U.S. patent application number 14/371819 was filed with the patent office on 2014-11-27 for formulation and method for increasing oral bioavailability of drugs.
The applicant listed for this patent is YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.. Invention is credited to Irina Cherniakov, Abraham J. Domb, Anna Elgart, Amnon Hoffman.
Application Number | 20140348926 14/371819 |
Document ID | / |
Family ID | 47678957 |
Filed Date | 2014-11-27 |
United States Patent
Application |
20140348926 |
Kind Code |
A1 |
Hoffman; Amnon ; et
al. |
November 27, 2014 |
FORMULATION AND METHOD FOR INCREASING ORAL BIOAVAILABILITY OF
DRUGS
Abstract
The application discloses a formulation and method for
increasing bioavailability of an orally administered drug.
Inventors: |
Hoffman; Amnon; (Jerusalem,
IL) ; Domb; Abraham J.; (Efrat, IL) ; Elgart;
Anna; (Mevaseret Zion, IL) ; Cherniakov; Irina;
(Gan Yavne, IL) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF
JERUSALEM LTD. |
Jerusalem |
|
IL |
|
|
Family ID: |
47678957 |
Appl. No.: |
14/371819 |
Filed: |
January 17, 2013 |
PCT Filed: |
January 17, 2013 |
PCT NO: |
PCT/IL2013/050047 |
371 Date: |
July 11, 2014 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
61704893 |
Sep 24, 2012 |
|
|
|
61696540 |
Sep 4, 2012 |
|
|
|
61615457 |
Mar 26, 2012 |
|
|
|
61588341 |
Jan 19, 2012 |
|
|
|
Current U.S.
Class: |
424/489 ;
514/291; 514/469; 514/597; 514/729 |
Current CPC
Class: |
A61K 31/17 20130101;
A61K 31/343 20130101; A61K 31/17 20130101; A61K 31/366 20130101;
A61K 31/352 20130101; A61K 47/14 20130101; A61K 31/436 20130101;
A61K 36/67 20130101; A61K 47/24 20130101; A61K 31/7048 20130101;
A61K 9/127 20130101; A61K 36/67 20130101; A61K 31/436 20130101;
A61K 47/22 20130101; A61K 9/5123 20130101; A61K 31/7048 20130101;
A61K 9/10 20130101; A61K 31/366 20130101; A61K 31/05 20130101; A61K
45/06 20130101; A61K 31/05 20130101; A61K 31/352 20130101; A61K
38/00 20130101; A61K 31/343 20130101; A61K 9/0019 20130101; A61K
2300/00 20130101; A61K 2300/00 20130101; A61K 2300/00 20130101;
A61K 2300/00 20130101; A61K 2300/00 20130101; A61K 2300/00
20130101; A61K 2300/00 20130101; A61K 2300/00 20130101 |
Class at
Publication: |
424/489 ;
514/469; 514/291; 514/729; 514/597 |
International
Class: |
A61K 9/51 20060101
A61K009/51; A61K 31/436 20060101 A61K031/436; A61K 31/05 20060101
A61K031/05; A61K 9/10 20060101 A61K009/10; A61K 47/22 20060101
A61K047/22; A61K 47/24 20060101 A61K047/24; A61K 47/14 20060101
A61K047/14; A61K 31/343 20060101 A61K031/343; A61K 31/17 20060101
A61K031/17 |
Claims
1-48. (canceled)
49. A composition for oral administration of at least one drug,
said composition comprising: a) a dispersible concentrate, wherein
it is capable of forming, upon contact with an aqueous solution,
particles of a size of less than about 500 nm, said dispersible
concentrate comprising: (i) at least one surfactant; (ii) at least
one solid component at room temperature; and (iii) an amphiphilic
solvent; b) an amount of at least one piperine, piperine analog or
isomer thereof, sufficient to increase the bioavailability of said
composition.
50. The composition according to claim 49, further comprising at
least one drug.
51. The composition according to claim 49, wherein the surfactant
is a combination of at least one high HLB (hydrophilic/lipophilic
balance) surfactant, having an HLB of at least about 8, with at
least one surfactant being a low HLB surfactant having an HLB of
less than about 5.
52. The composition according to claim 49, further comprising a
phospholipid.
53. The composition according to claim 49, further comprising a
fatty acid ester.
54. The composition according to claim 49, wherein said amphiphilic
solvent is selected from the group consisting of lower alkyl esters
of lactic acid, lower alkyl lactone esters and
N-methylpyrrolidone.
55. The composition according to claim 49, wherein said piperine is
obtained from Piper longum or Piper nigrum.
56. The composition according to claim 50, wherein said drug is a
lipophilic compound or a mixture of at least two lipophilic
compounds.
57. The composition according to claim 56, wherein the lipophilic
compound is a cannabinoid, a derivative or a synthetic analog
thereof, or a mixture of cannabinoids.
58. The composition according to claim 50, wherein the composition
and at least one drug are formulated for administration in the same
pharmaceutical formulation.
59. The composition according to claim 50, wherein the composition
and drug are formulated for administration in different
pharmaceutical formulations.
60. The composition according to claim 50, wherein said at least
one drug is a cannabinoid, a derivative or a synthetic analog
thereof, or a mixture of cannabinoids.
61. The composition according to claim 60, wherein said cannabinoid
being selected from the group consisting of tetrahydrocannabinol,
cannabidiol (CBD), cannabinol, cannabigerol,
tetrahydrocannabivarin, cannabidivarin and cannabichromene.
62. A method for increasing the bioavailability of a drug in a
mammal in need of said drug, the method comprising orally
administering: (1) said drug, and (2) a composition according claim
49, wherein said at least one piperine, piperine analog or isomer
thereof being present in said composition in an amount sufficient
to provide a greater bioavailability of said drug than
bioavailability of said drug in the absence of said at least one
piperine, piperine analog or isomer thereof.
63. The method according to claim 62, wherein said composition
being administered substantially simultaneously with the drug.
64. The method according to claim 62, wherein said composition and
drug are sequentially administered.
65. The method according to claim 62, wherein the drug is
administered in at least one dose within 24 hrs after
administration of the dose of said composition.
66. The method according to claim 62, for treatment of at least one
disease or disorder.
67. The method according to claim 62, wherein said at least one
drug is a cannabinoid, a derivative or a synthetic analog thereof,
or a mixture of cannabinoids.
68. The method according to claim 62, wherein said drug is a
cannabinoid being selected from the group consisting of
tetrahydrocannabinol, cannabidiol (CBD), cannabinol, cannabigerol,
tetrahydrocannabivarin, cannabidivarin and cannabichromene.
Description
FIELD OF THE INVENTION
[0001] The present invention pertains to a formulation and method
for increasing the oral bioavailability of drugs by utilizing
advanced pro-nano lipospheres (PNL) and PNL incorporating
piperine.
BACKGROUND OF THE INVENTION
[0002] Many dispersion systems are currently in use as, or being
explored for use as carriers of substances, particularly
biologically active compounds. These systems are designed to
protect the substance from the environment during delivery and to
provide a controlled release of the substance to a targeted area.
In some cases, the goal is to target specific sites in the body
using the dispersion. In other cases, the goal is to prepare a drug
carrier system that acts as a reservoir at the site of injection.
Dispersion systems used for pharmaceutical and cosmetic
formulations can be categorized as either suspensions or particles
ranging in size from a few nanometers up to hundreds of microns,
dispersed in an aqueous or non-aqueous medium using suspending
agents. Solid particles include microspheres, microcapsules,
nanoparticles and nanospheres.
[0003] One of the in situ methods of preparation of lipospheres
with a particle size below 100 nanometers was developed by using a
dispersible pre-concentrate system [1]. This delivery system,
termed pro-nanoliposphere (LIPOSPHERES), is based on a solution
containing a drug, a triglyceride, a phospholipid and other
additives, in a mixture of common surfactants, and an organic
solvent that is miscible with all components. This solution
spontaneously forms nanoparticles when in an aqueous media, and
even in vivo, e.g., the upper GI lumen content.
[0004] U.S. Pat. No. 7,919,113 [2] discloses dispersible
concentrate preparations (nano-lipospheres) for the solubilization
of lipophilic drugs to enhance the bioavailability of water
insoluble drugs.
[0005] When given orally, a drug is absorbed into the enterocyte
monolayer in the basolateral side of the intestine, where it can
undergo metabolism and/or efflux back into the lumen by
trans-membranal transporters. From the apical side of the
entrocytes the drug is delivered via the portal vein to the liver
and thereafter into the systemic blood circulation. Bioavailability
is defined as the fraction of an administered dose of unchanged
drug that reaches the systemic circulation. By definition, when a
medication is administered intravenously, its bioavailability is
100%.
[0006] Research in the field of drug absorption has focused on ways
to increase drug efficacy by increasing drug absorption. To this
end, methods have been used to increase drug absorption using
liposomes as carriers and by designing more lipophilic drugs.
However, these methods have not been successful in circumventing
liver biotransformation and biliary secretion of drugs.
[0007] Thus, when a medication is orally administered, its
bioavailability generally decreases due to incomplete absorption
and first-pass metabolism and also may vary from patient to
patient. Bioavailability is one of the essential tools in
pharmacokinetics, as it must be considered when calculating dosages
for none intravenous routes of administration.
[0008] Despite the great advancements in the area of various drug
delivery systems such as nano-lipospheres, many drugs are prone to
poor oral bioavailability due to biological barriers at the
enterocyte level, termed "intestinal first pass metabolism". These
biological processes include Phase I metabolism, namely oxidative
enzymes, and Phase II metabolism including conjugation, sulphation
and glucuronidation by intestinal enzymes. In addition, the poor
oral bioavailability is attributed to efflux transporters e.g.
permeability-glycoprotein (P-gp) at the enterocyte luminal membrane
[3].
[0009] P-gp can efflux out a variety of drugs from cells which
ultimately lead to unsuccessful drug therapy. It also affects
various pharmacokinetic parameters of drugs, such as P-gp
substrates like absorption, distribution, metabolism and excretion
from the body which leads to modified bioavailability and possible
adverse drug reactions. Thus, it is believed that the
P-glycoprotein efflux pump prevents certain pharmaceutical
compounds from transversing the mucosal cells of the small
intestine and, therefore, from being absorbed into the systemic
circulation.
[0010] Knowledge of the approaches to circumvent P-gp efflux pump
is critical for targeted drug therapy and formulation design and
development of dosage forms. It is established that drugs and
excipients interact with P-gp in a complicated procedure and
information of its mechanism of interaction are still unclear.
[0011] While there are several methods to inhibit metabolic and
efflux processes by pharmacological agents, there are limited
pharmaceutical solutions to overcome this problem. Much more
difficult is the case of Phase II metabolism, where there are
currently no effective technologies that control this biological
process in the clinical setting.
[0012] Piperine is an alkaloid responsible for the pungency of
black pepper (Piper nigrum), and long pepper (Piper longum), along
with chavicine (an isomer of piperine). The active compound in both
Piper longum and Piper nigrum is piperine (1-piperoyl piperidine),
which has been shown to possess bioavailability enhancing activity
with various structurally and therapeutically diverse drugs. It has
been found that piperine bioavailability-enhancing property may be
attributed to increased absorption, which may be due to alteration
in membrane lipid dynamics and change in the conformation of
enzymes in the intestine [4].
[0013] Kulkarni S K, et al., [5] examined the antidepressant effect
of curcumin with piperine and concluded that the combination of
piperine (2.5 mg/kg, i.p., 21 days), with curcumin (20 and 40
mg/kg, i.p.) showed significant potentiation of its
anti-immobility, neurotransmitter enhancing and monoamine oxidase
inhibitory (MAO-A) effects as compared to the effect curcumin
alone.
[0014] Pattanaik S, et al., [6] examined the effect of simultaneous
administration of piperine (20 mg, p.o.) on plasma concentration of
carbamazepine (300 mg or 500 mg), twice daily, in epileptic
patients and found that piperine significantly increased the mean
plasma concentrations of carbamazepine in both dose groups.
[0015] U.S. Pat. No. 5,439,891 [7] discloses that the active
constituent of Piper longum and Piper nigrum, piperine, was shown
to increase bio-availability of certain anti-tubercular and
anti-leprosy drugs like rifampicin, isoniazid, pyrazinamide,
ethambutol and dapsone.
[0016] U.S. Pat. No. 5,616,593 [8] discloses use of piperine to
improve bioavailability of substances used to treat disease of
cardiovascular system, central nervous system, gastrointestinal
treatment or hemopoetic system.
[0017] U.S. Pat. No. 5,536,506 [9] and U.S. Pat. No. 5,972,382 [10]
disclose compositions and methods for the improvement of
gastrointestinal absorption and systemic utilization of nutrients
and nutritional supplements, wherein the compositions comprise a
minimum of 98 percent of pure alkaloid piperine.
REFERENCES
[0018] [1] Bekerman, T., J. Golenser, and A. Domb. J Pharm Sci.,
93(5): 1264-70, 2004. [0019] [2] U.S. Pat. No. 7,919,113. [0020]
[3] Lipinski, C. A., et al., Adv Drug Deliv Rev., 46(1-3): p. 3-26,
2001. [0021] [4] PATIL UK, International Journal of Recent Advances
in Pharmaceutical Research, 4:16-23, October 2011. [0022] [5]
Kulkarni S. K., Bhutani M. K., Bishnoi M. Psychopharmacology
(Berl), 201:435-442, 2008. [0023] [6] Pattanaik S, et al.,
Phytother Res. 23(9):1281-6, 2009. doi: 10.1002/ptr.2676. [0024]
[7] U.S. Pat. No. 5,439,891. [0025] [8] U.S. Pat. No. 5,616,593.
[0026] [9] U.S. Pat. No. 5,536,506. [0027] [10] U.S. Pat. No.
5,972,382. [0028] [11] Koul S, et al. Bioorg Med Chem.,
8(1):251-68. 2000.
SUMMARY OF THE INVENTION
[0029] The present invention is concerned with optimization of drug
bioavailability. It is the purpose of the present application to
provide a superior nano-particulate formulation, e.g., delivery
system, for enhancing the oral bioavailability of a broad range of
drugs, having a low oral bioavailability, by combining its
administration with pro-nano lipospheres (PNLs) or with PNL loaded
piperine (herein referred to in short as piperine-PNL). The PNL or
piperine-PNL technology enhances the oral bioavailability of drugs,
in particular lipophilic drugs, which bioavailability is limited
not only due to Phase I metabolism and/or P-gp efflux but also due
to direct Phase II metabolism in the intestine.
[0030] The inventors of the present invention have developed a PNL
and piperine-PNL systems that has multiple concerted productive
activities that altogether synergistically enhances bioavailability
of poor bioavailable drugs and results in more stable, and less
variable, absorption of the drugs from the gastrointestinal tract
and thereby also to a reduction of the required dose of the
drug.
[0031] The development of piperine-PNL is based on a PNL
pro-nano-dispersion system which employs an orally administered
mixture of lipids, surfactants and co-solvent, herein referred to
as a "dispersible concentrate". This concentrate may be
administered orally in combination with an active agent which is
administered either within the pro-nanodispersion formulation or
provided shortly before or after the administration of the PNL
dosage unit (e.g. soft gelatin capsule). Thus, when reaching the
aqueous phase of the gastro intestinal (GI) tract, the PNL is
released and spontaneously forms drug encapsulated nano-particles
with a particle diameter of 500 nm or less.
[0032] The piperine-PNL utilizes this concept and in a synergistic
manner with piperine, a natural food derived component and adds to
the absorption enhancement properties of the PNL disclosed in U.S.
Pat. No. 7,919,113 [2], herein incorporated by reference.
[0033] Furthermore, due to piperine's poor aqueous solubility and
fairly good lipid solubility, it can be readily incorporated into
the lipid PNL core. Incorporating piperine into PNL presents an
opportunity to manipulate the critical systems accounted for the
marked first pass effect of various drugs (e.g. cannabidiol and
tetrahydrocannabinol). The incorporation of piperine increases the
piperine's concentration that reaches the intestine and the liver,
and potentially competitively inhibits the drugs' metabolism in
those metabolic sites. As a result the oral bioavailability of the
various drugs could be further enhanced as compared to the
administration of the drugs in PNL not containing piperine.
[0034] As known to a person of skill in the art, the increase in
drug bioavailability is defined as an increase in the Area Under
the Curve (AUC); being the integrated measure of systemic drug
concentrations over time, in units of mass-time/volume. The AUC
from time zero (the time of dosing) to time infinity (when no drug
remains in the body) following the administration of a drug dose is
a measure of the exposure of the patient to the drug.
[0035] The inventors of the present invention have surprisingly
found that administration of cannabidiol (CBD) in piperine-PNLs
resulted in significantly higher oral relative bioavailability in
comparison to administration of cannabidiol in PNLs without
piperine. Oral administration of CBD-piperine-PNL resulted in
significantly higher AUC and C.sub.max values by 5 fold and 15
fold, respectively, as compared to control, (as further described
hereinbelow) attesting to the increase in the oral bioavailability
of drugs that is attributed to the piperine-PNLs system of the
present invention.
[0036] Thus, in one aspect of the present invention, there is
provided a composition (formulation or a drug delivery system) for
oral administration of at least one drug, said composition
comprising: [0037] a) a dispersible concentrate, characterized by
being capable of forming, upon contact with an aqueous solution,
particles of a size of less than about 500 nm, said dispersible
concentrate comprising: [0038] (i) at least one surfactant; [0039]
(ii) at least one solid component at room temperature; and [0040]
(iii) an amphiphilic solvent; [0041] b) an amount of at least one
piperine, piperine analog or isomer thereof, e.g., in an amount
sufficient to increase the bioavailability of said composition.
[0042] The "dispersible concentrate" is a composition which
spontaneously forms a nano-particulate dispersion in an aqueous
medium, for example in water upon dilution, or in the gastric
juices after oral administration. The "dispersible concentrate"
includes those compositions that form solid particles having a mean
diameter of less than about 500 nm upon contact with an aqueous
medium.
[0043] The "aqueous medium," refers to a water based medium, i.e.,
a liquid medium in which water is the major component. In
accordance with the present invention, the aqueous medium may be
the digestive fluid formed in the stomach (e.g., gastric fluid
formed by cells lining the stomach), GI tract fluids or any liquid
medium, in vivo or ex vivo in which the herein defined dispersible
concentrate is dissolved.
[0044] The "surfactant" is any amphiphilic compound generally
recognized in the art as having surface active qualities.
Surfactants generally include anionic, cationic, nonionic, and
zwitterionic compounds, as further described herein. In some
embodiments, the surfactant is a combination of at least one high
HLB (hydrophilic/lipophilic balance) surfactant having an HLB of at
least about 8, with at least one surfactant being a low HLB
surfactant having an HLB of less than about 5.
[0045] In some embodiments, the surfactant is selected from
polyoxyethylene, sorbitanmonolaurate, sorbitanmonooleate and
mixtures thereof.
[0046] In other embodiments, the composition further comprises an
ethoxylated fat and fatty compounds. Some non-limiting examples
being selected from polyethyleneglycol-hydrogenated castor oil
(e.g. cremophor and cremophor RH).
[0047] In still other embodiments, the composition further
comprises a phospholipid selected from an egg phospholipid, a soy
phospholipid and lecithin of various grades and purities.
[0048] In still yet other embodiments, the composition further
comprises a fatty acid ester, e.g., a fatty acid ester that is a
solid fat at room temperature such as tricaprin.
[0049] In some embodiments, the composition of the present
invention is of a particle size that is less than about 200 nm.
[0050] In other embodiments, the composition is of a particle size
that is less than about 100 nm.
[0051] In still other embodiments, the composition is of a particle
size that is less than about 50 nm.
[0052] As used herein, the term "solid component" refers to solid
materials that are solid at room temperature (defined herein as
25.degree. Celcius) and that dissolve in the dispersible
concentrate and which upon dispersion in aqueous medium becomes
part of the formed solid nanoparticles.
[0053] Some non-limiting examples of solid components, in
accordance with the present invention include fatty acids, fatty
amines and fatty alcohols or their respective esters or amides that
melt at a temperature above 25.degree. C.; polymers that are solids
at 25.degree. C., and paraffins and waxes that are solid at
25.degree. C.
[0054] In some embodiments, the fatty acid esters are selected from
mono-, di-, and triglycerides and fatty acid esters with long and
short chain alcohols that are solids at 25.degree. C. In other
embodiments, the solid components are selected from tricaprin,
trilaurin, trimyristine, tripalmitin, tristearin and mixtures
thereof that are solids at 25.degree. C.
[0055] In still other embodiments, the solid components are
compounds that solidify in situ upon dispersion in aqueous medium,
e.g., partially or fully hydrogenated vegetable oil that are solid
at 25.degree. C.
[0056] The "amphiphilic solvent" utilized in a composition of the
invention is selected from lower alkyl (having between 1 and 8
carbon atoms) esters of lactic acid, lower alkyl (having between 1
and 8 carbon atoms) lactone esters and N-methylpyrrolidone. Some
non-limiting examples of lower alkyl esters include methyl, ethyl,
propyl, isopropyl, butyl, hexyl, pentyl and octyl esters.
[0057] In some embodiments, the amphiphilic solvent is selected
from methyl lactate, ethyl lactate, propyl lactate, spironolactone
and N-methylpyrrolidone.
[0058] In some embodiments, the amphiphilic solvent is a
combination of a lower alkyl ester of lactic acid with
N-methylpyrrolidone.
[0059] In some embodiments, the amphiphilic solvent comprises a
combination of a solvents selected from the family of lower alkyl
esters of lactic acid together with a solvent selected from the
family of alkyl lactone esters or N-methylpyrrolidone.
[0060] In other embodiments, the amphiphilic solvent is combined
with a hydrophilic organic solvent such as ethylene glycol,
glycofurol or PEG 400.
[0061] As known, "Piperine" is
(E,E)1-[5-(1,3-benzodioxyl-5-yl)-1-oxo-2,4-pentadenyl]piperidine
being the main constituent of many Piper species. In accordance
with the present invention, piperine may be obtained commercially
or from a number of species of peppers from the Piperaceae family
(e.g., Piper nigrum, P. longum, P. tuberculatum, P. hancei, P.
hispidum, P. retrofactum, P. attenuatum, P. genueense, P. chaba, P.
aurantiacum, P. auritum, P. cubeba, P. peltatum, P. umbellatum and
P. mystheticum. P. nigrum).
[0062] In some embodiments, piperine utilized in accordance with
the invention is obtained from Piper longum or Piper nigrum.
[0063] In other embodiments, piperine utilized in accordance with
the invention is in pure form (e.g. piperine at a purity of
>95%).
[0064] In other embodiments, piperine is a piperine analog (e.g.,
derivatives in which the piperidine ring is substituted, e.g., by
an amino group, or an ester group (e.g., C.sub.1-6 alkyl esters) of
metabolites containing an OH group as described, for example in
Koul S, et al. [11]. The piperine analogues may be synthetically
obtained or produced from a natural source.
[0065] In other embodiments, piperine is a piperine isomer (e.g.
chavicine) In some embodiments, the amount of piperine in the
composition of the invention is in the range of about 0.1 to about
10 mg/kg body weight.
[0066] In accordance with the present invention, the piperine,
piperine analog or isomer thereof may or may not be incorporated
into the pro-nano lipospheres formed upon contact of the
dispersible concentrate with an aqueous solution and may also be
partially incorporated into said lipospheres.
[0067] The composition comprising piperine (and/or a piperine
analog or isomer thereof) and referred to in short as piperine-PNL
is also related to hereinafter as an empty composition, as compared
to a composition comprising a drug (described hereinbelow).
[0068] The increase in drug bioavailability attributable to
administration of the piperine, as described herein, can be
determined by measuring total systemic drug concentrations over
time after administration of a composition comprising piperine and
the drug as compared to after administration of the drug alone,
defined as an increase in the Area Under the Curve (AUC) as
described hereinabove.
[0069] Thus, when the piperine, piperine analog or isomer thereof
are used in sufficient amounts in the composition of the present
invention, the activity of P-gp and Cytochrome P.sub.450 3A4
(abbreviated CYP3A4) is reduced.
[0070] The sufficient amounts of piperine, piperine analog or
isomer thereof are the amounts necessary to elevate the systemic
concentrations of the drug over time and can be determined by
measuring total systemic drug concentrations as readily recognized
by the skilled artesian.
[0071] The increase in drug bioavailability achieved by the use of
the composition of the invention and by practicing the methods
described herein also results in reduction in inter-individual and
intra-individual variation in oral bioavailability of the drug,
enabling the practitioner to better standardize drug administration
regimens using the piperine-PNL system of the present
invention.
[0072] In some embodiments, the empty composition as defined herein
comprises at least one drug.
[0073] The "drug" is generally any chemical capable of
administration to a mammal, which modifies or alters the mammal's
physiology. Thus, in accordance with the present invention the
"drug" is any substance intended for use in the treatment or
prevention of disease or a disorder. Drugs include synthetic and
naturally occurring substances as well as recognized
pharmaceuticals, such as those listed in the United States
Pharmacopeia, (USP36 NF31, 2013: U.S. Pharmacopoeia National
Formulary United States Pharmacopeial Convention 36th Edition 2012;
ISBN 978-3769258844).
[0074] In some embodiments, the drug is a lipophilic compound or a
mixture of two or more different lipophilic compounds. As used
herein, the "lipophilic compound" is a compound that in its
non-ionized form is more soluble in lipid or fat than in water.
[0075] In some embodiments, the lipophilic compound is a compound
having a LOG P.gtoreq.2 (Log P being an estimate of a compound's
overall lipophilicity as recognized by the skilled artesian).
[0076] The lipophilic compounds, as described herein, are generally
compounds which have limited oral bioavailability due to first pass
metabolism, by (1) Phase I metabolic enzymes e.g. CYP3A4 (2)
intra-enterocytes phase II metabolic enzymes (e.g.
UDP-glucuronosyltransferases, sulfotransferases,
N-acetyltransferases, glutathione S-transferases and
methyltransferases; (3) efflux from the enterocytes back to the
gastrointestinal lumen by efflux pumps (responsible for the export
of many lipophilic and ampiphilic drugs that impedes their
intracellular absorption) such as P-gp (that is extensively
distributed and expressed in the intestinal epithelium), and thus
are associated with poor and variable oral bioavailability.
[0077] In some embodiments, the lipophilic compounds are compounds
categorized as Class II of the Biopharmaceutical Classification
System (BCS) proposed by Amidon, G. L., et al. Pharm Res.,
12(3):413-20, 1995. BCS is an experimental model that measures
permeability and solubility under prescribed conditions. BCS Class
II compounds are considered to have low solubility and high
permeability and Class IV compounds characterized as having low
solubility and low permeability.
[0078] Some non-limiting examples of lipophilic compounds that are
subjected to both CYP3A4 and P-gp efflux include amiodarone,
tacrolimus, cannabidiol, cyclosporine, indinavir, nicardipine,
quinidine and verapamil.
[0079] Some non-limiting examples of compounds that are subjected
to intestinal CYP3A4 metabolism and which are not subjected P-gp
efflux substrates include felodipine, midazolam, nifedipine and
propafenone.
[0080] Some non-limiting examples for compounds subjected to P-gp
efflux and which are not subjected to CYP3A4 metabolism substrates
are talinolol and fexofenadine.
[0081] In some embodiments, the lipophilic compound is a BCS Class
IV compound (e.g. hydrochlorothiazide, amphothericin B).
[0082] Examples for additional poorly water soluble compounds with
oral bioavailability affected by intestinal and hepatic first pass
metabolism and subjected to P-gp efflux are amlodipine, diltiazem,
felodipine, nicardipine, nifedipine, nimodipine, nisoldipine,
verapamil, sirolimus, tacrolimus, atorvastatin, lovastatin,
simvastatin, fexofenadine, buspirone, carbamazepine, pimozide,
midazolam, triazolam, albendazole, itraconazole, cisapride,
colchicine, sildenafil, amphotericine B, steroids, polyphenols and
canbinoids.
[0083] In some embodiments, the lipophilic compound is a
nutraceutical, a food product or a homeopathic agent (e.g.,
polyphenols, carotenoids, cyclopsporine).
[0084] In other embodiments, the drug is a lipophilic compound or a
mixture of at least two lipophilic compounds.
[0085] In some embodiments, the lipophilic compound is
Amiodarone.
[0086] In other embodiments, the lipophilic compound is
Tacrolimus.
[0087] In still other embodiments, the lipophilic compound is
Talinolol.
[0088] In still yet other embodiments, the lipophilic compound is
cyclosporine A.
[0089] In additional embodiments, the lipophilic compound is a
cannabinoid, a derivative or a synthetic analog thereof, or a
mixture of cannabinoids. Some non-limiting examples of cannabinoids
are tetrahydrocannabinol, cannabidiol (CBD), cannabinol,
cannabigerol, tetrahydrocannabivarin, cannabidivarin and
cannabichromene.
[0090] In accordance with the present invention, when the
composition comprises a drug, as defined herein, the drug may or
may not be incorporated into the pro-nano lipospheres formed upon
contact of the dispersible concentrate with an aqueous solution and
may also be partially incorporated into said lipospheres.
[0091] In some embodiments, the composition of the invention
further comprises a pharmaceutically acceptable carrier and/or
excipient, which physiologically tolerable and do not typically
produce an allergic or similar untoward reaction, such as gastric
upset, dizziness and the like, when administered to a mammal such
as a human.
[0092] The composition of the present invention (either empty
composition or composition comprising a drug) is a composition
suitable for administration by the oral route (e.g. buccal,
sublabial, sublingual) using a swallowable capsule or any other
medicament formed in a relatively stable shell (e.g. soft gel
capsule, pill, tablet, granule).
[0093] In some embodiments, the composition and drug are
administered in the same pharmaceutical formulation, i.e., in a
single unit dosage form.
[0094] In other embodiments, the composition and drug are
administered in a different pharmaceutical formulation, i.e., in a
separate unit dosage form.
[0095] In accordance with the present invention, the herein defined
composition may also be diluted or combined in a food or beverage
prior to feeding to a subject.
[0096] In another aspect of the present invention there is provided
a method for increasing the bioavailability of a drug, the method
comprising orally co-administering to a mammal (human or non-human)
in need of treatment by said pharmaceutical drug:
[0097] (1) said drug, and
[0098] (2) an empty composition, according to the present
invention, wherein said at least one piperine, piperine analog or
isomer thereof being present in said composition in a sufficient
amount to provide bioavailability of said drug greater than
bioavailability of said drug in the absence of said at least one
piperine, piperine analog or isomer thereof.
[0099] The herein described method can be used to modify the
pharmacokinetics of drugs by multiple mechanisms, including
inhibition of phase I and phase II metabolism, in the intestine and
in the liver and intestinal inhibition of P-gp efflux pumps.
[0100] In some embodiments, the empty composition is
co-administered substantially simultaneously with the drug (either
less than 20 min before, less than 20 min after or together with
the drug).
[0101] In other embodiments, the empty composition and drug are
sequentially administered.
[0102] The term "sequentially" or "sequentially administered" as
used herein is intended to mean that an empty composition is
administered before one or more subsequently administered drugs or
that the drug is administered before the empty composition.
[0103] In some embodiments, the empty composition is administered 0
minutes, 20 minutes, before the subsequently administered drug.
[0104] In other embodiments, the drug is administered 0 minutes, 20
minutes, before the subsequently administered empty
composition.
[0105] In some embodiments, the drug is administered in at least
one dose within 24 hrs after administration of the dose of the
empty composition; i.e., the empty composition is not administered
again before or with every administration of the drug, but may be
administered intermittently during the course of treatment.
[0106] In some embodiments, when the drug is administered before
the empty composition, clinical evaluation of the drug's effect
(e.g. on a disease state) and of the drug's plasma concentration
are measured (e.g. using methods well-established as common
practice in the art) and based on said measured parameters, a
decision of the amount of empty composition to be administered
thereafter or before the administration of the drug, is made.
According to such embodiments, depending on the type of disease to
be treated, the condition of the patient or any other parameters
that are readily apparent to the skilled artesian, the amount of
empty composition to be administered and/or amount of piperine in
said empty composition are determined.
[0107] Thus, in accordance with the present invention, the empty
composition and drug may be administered together, alternately or
intermittently in all of the various aspects of the invention,
depending on the type of drug, the type of disease to be treated
with the drug and/or any other considerations that are readily
apparent to skilled artesian.
[0108] In still another aspect of the present invention, there is
provided a process for preparing the composition of the invention,
said process comprising:
[0109] (a) dissolving the amphiphilic solvent and optionally
phospholipid (and optionally gently heating to achieve complete
dissolution of the phospholipid),
[0110] (b) adding at least one surfactant to the solution obtained
in step (a) (and optionally gently heating and stirring to obtain a
homogenous solution.
[0111] In some embodiments, said process further comprises a step
(c) of adding the drug (e.g. as a powder) to the pre-concentrate
formed in step (b) and optionally gently heating (e.g. at between
about 30.degree. C. and between about 50.degree. C.) and stirring
to obtain a homogenous solution which upon gentle agitation in
aqueous phase, spontaneously forms drug encapsulated
nano-dispersion.
[0112] When a piperine comprising composition is desired, piperine
(e.g. as a powder) may be added with the drug.
[0113] In some embodiments, the ratio of amphiphilic solvent and
phospholipid in step (a) of said process is between 8 and 1,
respectively.
[0114] In some embodiments, the ratio of amphiphilic solvent and
phospholipid I step (a) of said process is about 8:1,
respectively.
[0115] The present invention also contemplates the use of the
composition of the invention for the preparation of a medicament
for increasing the bioavailability of a drug.
[0116] The medicament may include pharmaceutically acceptable
carriers, for example, vehicles, adjuvants, excipients, or
diluents, which are well-known to those who are skilled in the art
and are readily available to the public. It is preferred that the
pharmaceutically acceptable carrier be one which is chemically
inert to the piperine-PNL and active drug and one which has no
detrimental side effects or toxicity under the conditions of
use.
[0117] Medicament formulations suitable for oral administration may
comprise (a) liquid solutions, such as an effective amount of the
composition dissolved in a non-aqueous diluent; (b) capsules,
sachets, tablets, lozenges, and troches, each containing a
predetermined amount of the composition, as solids or granules; (c)
powders; (d) suspensions in an appropriate non-aqueous liquid; and
(e) suitable non-aqueous emulsions. Liquid formulations may include
diluents, such as alcohols, for example, ethanol, benzyl alcohol,
and the polyethylene alcohols, either with or without the addition
of a pharmaceutically acceptable surfactant, suspending agent, or
emulsifying agent. Capsule forms may be of the ordinary hard- or
soft-shelled gelatin type containing, for example, surfactants,
lubricants, and inert fillers, such as lactose, sucrose, calcium
phosphate, and corn starch. Tablet forms may include one or more of
lactose, sucrose, mannitol, corn starch, potato starch, alginic
acid, microcrystalline cellulose, acacia, gelatin, guar gum,
colloidal silicon dioxide, talc, magnesium stearate, calcium
stearate, zinc stearate, stearic acid, and other excipients,
colorants, diluents, buffering agents, disintegrating agents,
moistening agents, preservatives, flavoring agents, and
pharmacologically compatible carriers. Lozenge forms may comprise
the composition in a flavor, usually sucrose and acacia or
tragacanth, as well as pastilles comprising the composition in an
inert base, such as gelatin and glycerin, or sucrose and acacia,
emulsions, gels, and the like containing.
[0118] In another one of its aspects the present invention provides
the use of the composition of the invention for increasing the
bioavailability of a drug.
[0119] In still another one of its aspects the present invention
provides the use of the composition of the invention for the
preparation of a medicament for the treatment of at least one
disease and/or disorder.
[0120] In an additional aspect, the present invention provides the
composition of the invention for use in the treatment of at least
one disease and/or disorder.
[0121] The present invention also contemplate the use of the
composition of the invention for treating at least one disease
and/or disorder.
[0122] In some embodiments, the disease is a disease treatable with
at least one cannabinoid and/or a derivative thereof.
[0123] The "disease treatable with at least one cannabinoid or a
derivative thereof" generally refers to a disease or disorder
selected from intractable cancer pain, neuropathic and chronic
pain, postoperative pain, rheumatoid arthritis, multiple sclerosis
and spasticity, fibromialgia, inflammation, gastrointestinal
disorders (e.g. nausea and vomiting, motility disorders), acute
schizophrenia, cancer, tics and behavioral problems experienced by
patients with tourette's syndrome, parkinson's disease,
huntington's disease, diabetes and diabetic complications,
cerebrovascular disorders and glaucoma.
[0124] The term "treatment" or any lingual variation thereof is
used herein to denote treating the disease, disorder or condition,
or ameliorating, alleviating, reducing, or suppressing symptoms of
the disease, or slowing or stopping the progress of the
disease.
[0125] In still another one of its aspects, the present invention
provides the use of the composition of the invention in combination
with other therapeutic modalities.
[0126] As used herein, the terms "therapeutic modalities",
generally refers to any therapeutic agent, treatment or
protocol/method that can be used in the treatment or alleviation of
a disease or disorder or at least one symptom thereof.
[0127] In some embodiments, the therapeutic modality is selected
from chemotherapy, hormonal therapy, radiation therapy, surgery,
biological therapy and immunotherapy.
[0128] In some embodiments, the therapeutic modality is a non-drug
therapy.
[0129] Thus, according to this aspect of the invention, a subject
may be administered with a therapeutic agent (pertaining to the
other therapeutic modality) in accordance with the therapeutic
regimen that is dictated by said other therapeutic modality while
the composition of the invention may be sequentially or
substantially simultaneously administered in single or in multiple
unit dosage forms.
[0130] In accordance with the present invention, the administration
of the therapeutic agent pertaining to said other therapeutic
modality can be carried out by any appropriate route including, but
not limited to, oral routes, intravenous routes, intramuscular
routes or any other administration route that is suitable to
achieve the desirable effect of the other therapeutic modality.
[0131] In some embodiments, the composition of the invention is
used to treat at least one symptom of a disease or disorder treated
by said other therapeutic modality. For example, when the disease
is cancer and the therapeutic modality is indicated to eradicate
the cancer, the herein defined composition may be used to treat the
pain symptoms associated with the cancer.
[0132] In other embodiments, the composition of the invention is
used as an add-on (adjuvant) therapy to said other therapeutic
modality to augment the treatment of the disease or disorder to be
treated by said other therapeutic modality. In accordance with such
embodiments the administration of the composition of the invention
together with said other therapeutic modality results in more
efficacious treatment (e.g. shortening of the time period to
achieve remission, treatment and/or amelioration) of the disease or
disorder treated with said other therapeutic modality than would
have been obtained without the administration of the composition of
the invention.
[0133] Generally, when used in an add-on therapy, the composition
of the invention is administered less than 24 hours after the
initiation of treatment with said other therapeutic modality.
[0134] By yet another aspect, the present invention provides a kit
for oral administration of the composition of the invention, said
kit comprising:
[0135] a) an empty composition as defined herein;
[0136] b) instructions of use.
[0137] In some embodiments, the herein defined kit further
comprises at least one drug, as defined herein.
[0138] The components composed in any of the kits of the invention,
may be contained in a single vessel or holding unit or in separate
vessels and contain a label attached to or packaged with the
container that describes the contents of the vessels and provides
indications and/or instructions regarding administration of
contents of the vessels to a mammalian subject in need of treatment
with said kit(s). The kit form is particularly advantageous when
the components are contained in different vessels for
administration in different dosage amounts or when titration of the
individual components of the kit (e.g., dispersible concentrate,
piperine and drug) is desired by the prescribing physician.
[0139] The present invention also provides a composition for oral
administration of at least one drug, said composition comprising a
dispersible concentrate, characterized by being capable of forming,
upon contact with an aqueous solution, particles of a size of less
than about 500 nm, said dispersible concentrate comprising: [0140]
(i) at least one surfactant; [0141] (ii) at least one solid
component at room temperature; and [0142] (iii) an amphiphilic
solvent.
[0143] It should be noted that where various embodiments are
described by using a given range, the range is given as such merely
for convenience and brevity and should not be construed as an
inflexible limitation on the scope of the invention. Accordingly,
the description of a range should be considered to have
specifically disclosed all the possible sub-ranges as well as
individual numerical values within that range.
[0144] It is appreciated that certain features of the invention,
which are, for clarity, described in the context of separate
embodiments, may also be provided in combination in a single
embodiment. Conversely, various features of the invention, which
are, for brevity, described in the context of a single embodiment,
may also be provided separately or in any suitable sub-combination
or as suitable in any other described embodiment of the invention.
Certain features described in the context of various embodiments
are not to be considered essential features of those embodiments,
unless the embodiment is inoperative without those elements.
BRIEF DESCRIPTION OF THE DRAWINGS
[0145] In order to better understand the subject matter that is
disclosed herein and to exemplify how it may be carried out in
practice, embodiments will now be described, by way of non-limiting
example only, with reference to the accompanying drawings, in
which:
[0146] FIG. 1 presents comparative dissolution profile of AM
(Amiodarone) nano lipospheres containing soft gelatin capsules at
pH 6.8 and 1.2 (n=3 for each pH).
[0147] FIG. 2 presents plasma AM concentration--time plot
(mean.+-.S.E.M.) following PO administration of AM and AM-
nano-lipospheres, 12.5 mg/kg (n=6 for each group).
[0148] FIG. 3 present plasma CBD concentration--time plot
(mean.+-.S.E.M.) following PO administration of CBD and CBD nano
lipospheres, 12.5 mg/kg (n=6 for each group).
[0149] FIG. 4 presents plasma talinolol concentration-time plot
(mean.+-.S.E.M.) following per os (PO) administration 4 mg/kg of
talinolol vs. AM- nano-lipospheres (n=5 for each group).
[0150] FIG. 5 presents plasma (.mu.g/mL) and tissue (.mu.g/g)
concentrations of AM following PO administration of 12.5 mg/kg of
AM and AM nano-lipospheres for 5 days. Significant difference was
found both in plasma and in corresponding heart and liver
concentrations. (n=3 for each group).
[0151] FIGS. 6A-D present plasma AM concentration-time plot
(mean.+-.S.E.M.) following PO administration 12.5 mg/kg of AM vs.
AM- nano-lipospheres (A), AM vs. AM+blank nano-lipospheres (B), AM-
nano-lipospheres vs. AM+blank nano-lipospheres (C), and AM-
nano-lipospheres vs. AM- nano-lipospheres+blank nano-lipospheres in
the dose of 12.5 mg/kg (D). (n=6 for each group).
[0152] FIG. 7 presents plasma AM concentration-time plot
(mean.+-.S.E.M.) following PO administration of blank
nano-lipospheres following AM (12.5 mg/kg) administration after 2 h
or water following AM (12.5 mg/kg) administration after 2 h (n=3
for each group).
[0153] FIG. 8 presents mean IBI changes (as percentage from
baseline) following 12.5 mg/kg AM administration in 3 different
formulations: AM, AM nano-lipospheres, AM+Blank nano lipospheres
and administration of blank nano-lipospheres. The drug was
administered at t=60 min (n=6 for each group)
[0154] FIG. 9 presents mean HR changes (as percentage from
baseline) following 12.5 mg/kg AM administration in 3 different
formulations: AM, AM nano-lipospheres, AM+Blank nano lipospheres
and administration of blank nano-lipospheres. The drug was
administered at t=60 min (n=6 for each group).
[0155] FIG. 10 presents plasma concentration-time profile (.+-.SE)
obtained following IV administration of 12.5 .mu.g/kg
Amiodacore.RTM. and AM nano-lipospheres.
[0156] FIG. 11 presents papp (.+-.SEM) values of talinolol vs.
talinolol+blank nano-lipospheres in Caco-2 model in A to B and B to
A directions (n=3 for each group). Significantly higher
(p<0.001) Papp values of talinolol+blank nano-lipospheres vs.
talinolol were obtained in A to B direction. Significant
(p<0.001) reduction in Papp values obtained for talinolol+blank
nano-lipospheres vs. talinolol in B to A direction.
[0157] FIG. 12 presents the difference (p<0.01) found between
intact AM concentrations remaining following 120 min. incubation of
AM nano-lipospheres vs. AM in isolated rat CYP3A4 microsomes.
Significant difference (p<0.05) was found between testosterone
with blank nano-lipospheres vs. testosterone alone incubated under
the same conditions (n=3 for each study).
[0158] FIG. 13 presents TEER values (outer line chart) (.+-.SD) of
Caco-2 cells monolayers in the presence of blank nano-lipospheres
vs. buffer, which was used as a control (n=3). The embedded column
chart represents Papp values (.+-.SD) of mannitol across the Caco-2
monolayers in the presence of blank nano-lipospheres vs.
buffer.
[0159] FIG. 14 presents the percent of LDH release (relatively to
100% release control) upon incubation of Caco-2 cell with medium
containing various concentrations of blank nano-lipospheres.
Nano-lipospheres increased LDH release in concentration dependant
manner with highest toxicity obtained at 10% nano-lipospheres
concentration and negligible toxicity produce by nano-lipospheres
concentration of 1% and less.
[0160] FIG. 15 presents plasma CBD concentration-time plot
(mean.+-.S.E.M.) following PO administration of CBD, CBD-PNL and
CBD-Piperine-PNL to rats, CBD-15 mg/kg; Piperine 10 mg/kg (n=6 for
each group). (*) Significant difference (p<0.05) from CBD
corresponding value is found.
[0161] FIG. 16 presents plasma concentration vs. time plot for CBD
and Cannabidiol (CBD)-PNL with and without various absorption
enhancers: Resveratrol (CBD-Resveratrol-PNL), Curcumin 1% & 2%
(CBD-curcumin 1%-PNL and CBD-curcumin 2%-PNL, respectively) and
CBD-Piperine-PNL to rats, CBD-15 mg/kg; (n=6 for each group). *The
concentration of piperine and resveratrol in the formulation was
2%; **PNL--Pro-Nano-Lipospheres. ***CBD--Cannabidiol. (*)
Significant difference (p<0.05) from CBD corresponding value is
found. (.dagger.) Significant difference (p<0.05) from CBD-PNL
corresponding value is found.
DETAILED DESCRIPTION OF EMBODIMENTS
[0162] The present invention is thus based on the realization that
it is possible to increase the oral bioavailability of a drug, such
as a drug containing a lipophilic compound, by administering the
drug in a composition comprising pro-nano lipospheres incorporating
piperine.
[0163] The following specific examples illustrate various aspects
of the present invention, and are not intended to be limiting in
any way. For all examples, all the ingredients were dissolved in
the solvent using magnetic stirrer, and heated gently
(.about.40-45.degree. C.) for 15-45 minutes until the ingredients
were completely dissolved. To obtain particles, the concentrate
formulation was diluted in at least 10 volumes of water in aqueous
solution.
[0164] For all experiments described below, the particle size of
the diluted formulation was measured with VLA particle size
analyzer (Coulter N4 MD Submicron Particle Size Analyzer), suitable
for submicron particle size determination. About 75 .mu.l of the
concentrate formulation were added to five milliliters of water.
The particle size of the diluted formulation did not change when it
dispersed in five milliliters of 0.1N HCl solution. For all
experiments described below, unless otherwise stated, the active
pharmaceutical ingredient (API) was in the base form (and not in
the salt form).
Preparation of a Composition According to the Invention
[0165] The composition containing amiodarone HCl or tacrolimus,
solvent, TRC (tricaprin) or alternatively TRL (trilaurin), egg
phospholipid (Avanti, USA), Tween.TM. 20, SPAN.TM. 80 and
Cremophor.TM. was prepared as given in Table 1 (all amounts of
ingredients, in Table 1 as well as in the following tables, are
given in milligrams). All compositions had a particle size of less
than 100 nm. The particle size decreased as the amount of either
ethyl lactate or Poly Ethylene Glycol (PEG) 400 was increased.
Ethyl lactate was generally more effective than Poly Ethylene
Glycol (PEG) 400 for providing smaller size particles.
TABLE-US-00001 TABLE 1 Amiodarone Pre-concentrate Basic
Formulations Ingredient 1 2 3 4 5 6 Amiodarone HCL 10 10 10 10 20
20 Tricaprin 40 -- 40 -- -- 52 Trilaurin -- 40 -- 40 52 -- Egg
phospholipids 40 40 40 40 20 20 Tween.TM. 20 60 60 60 60 52 52
SPAN.TM. 80 40 40 40 40 52 52 Cremophor.TM. 52 20 20 20 52 52 Ethyl
lactate 160 160 -- -- 190 180 Poly Ethylene Glycol -- -- 160 160 --
-- (PEG) 400
Effect of Various Hydrophobic Pharmaceutical Active Ingredients
(API) and Vitamins on Particle Size
[0166] Different compositions containing various hydrophobic
Pharmaceutical Active Ingredients (API) and Vitamins were prepared
as described in Tables 2A and 2B. The effect of the API's on the
particle size when dispersed in water was examined Briefly, the
droplet size of compositions which included hydrophobic API had
small particle sizes (less than 100 nm) in cases of low API
concentration but the particle size was increased in cases that the
API concentration was higher (and was above 100 nm in some cases).
Similar phenomenon was received with the vitamins.
[0167] Other hydrophobic API's and Vitamins were also tested and
similar results were obtained (not shown in the next table). In all
cases, the pharmaceutical active ingredient (API) was in the base
form (and not in the salt form).
TABLE-US-00002 TABLE 2A Formulations of various hydrophobic API in
different amounts Ingredient 1 2 3 4 5 6 7 8 9 10 Trilaurin 40 40
40 40 40 40 40 40 40 40 Egg phospholipids 20 20 20 20 20 20 20 20
20 20 SPAN.TM. 80 40 40 40 40 40 40 40 40 40 40 Tween.TM. 20 40 40
40 40 40 40 40 40 40 40 Cremophor.TM. 40 40 40 40 40 40 40 40 40 40
Ethyl lactate 140 140 140 140 140 140 140 140 140 140 Soltanol 20
40 -- -- -- -- -- -- -- -- Flecaininde -- -- 20 40 -- -- -- -- --
-- Propafenone -- -- -- -- 20 40 -- -- -- -- Ezetimibe -- -- -- --
-- -- 20 40 -- -- Doxorudicin -- -- -- -- -- -- -- -- 20 40
TABLE-US-00003 TABLE 2B Formulations of various hydrophobic API and
Vitamins in different amounts Ingredient 1 2 3 4 5 6 7 8 9 10
Trilaurin 40 40 40 40 40 40 40 40 40 40 Egg phospholipids 20 20 20
20 20 20 20 20 20 20 SPAN.TM. 80 40 40 40 40 40 40 40 40 40 40
Tween.TM. 20 40 40 40 40 40 40 40 40 40 40 Cremophor.TM. 40 40 40
40 40 40 40 40 40 40 Ethyl lactate 140 140 140 140 140 140 140 140
140 140 Sildenafil 20 40 -- -- -- -- -- -- -- -- Tadalafil -- -- 30
60 -- -- -- -- -- -- Vardenafil -- -- -- -- 20 40 -- -- -- --
Maxiletine -- -- -- -- -- -- 20 40 -- -- Vitamin D2 -- -- -- -- --
-- -- -- 40 -- Vitamin D3 -- -- -- -- -- -- -- -- -- 40
Amiodarone HCL Pre-Concentrate Formation
[0168] The final Amiodarone HCL composition was based on
preliminary formulation optimization studies and selected according
to optimal solubilization capacity of the active ingredient and
smallest particle size obtained upon dilution in aqueous phase, as
described above. Initially amphiphilic co-solvent (ethyl lactate)
and phospholipid (lecithin) at the ratio of 8:1 respectively were
placed in a clean scintillation tube and heated to 40.degree. C.
until the lecithin was completely dissolved. Then triglyceride
(trilaurin), polyoxyl 40-hydroxy castor oil, Tween 20, and Span 80
at the ratio of 1:1:1:1 were added; the mixture was gently stirred
and heated to 45.degree. C. until a homogenous solution was formed.
Further, Amiodarone HCL powder was added, forming the AM
pre-concentrate containing 3% AM. This pre-concentrate was gently
stirred and heated to 45.degree. C. till homogenous solution was
formed. Upon gentle agitation in aqueous phase, this
pre-concentrate spontaneously forms drug encapsulated O/W
nano-emulsion. Amiodacre.RTM. ampoules content (50 mg/ml Amiodarone
HCl, 20.2 mg/mL benzyl alcohol and 100 mg/mL Tween 80 in water) was
used as control AM throughout all in-vivo and in-vitro studies.
[0169] Talinolol pre-concentrate was prepared by the same method as
amiodarone HCL pre-concentrate, except for the different
triglyceride that was used. For the preparation of the
pre-concentrate a triglyceride; lecithin was used. The
concentration of the compound i.e. talinolol in the pre-concentrate
was 1%.
[0170] Blank pre-concentrate was prepared by the same method as
miodarone HCL preconcentrate, except no active ingredient was
added.
[0171] Tacrolimus nano lipospheres were prepared by the same method
to produce preconcentrate containing 5% tacrolimus. Prograf.RTM.
capsules were used as control tacrolimus throughout in-vivo
studies.
Cannabidiol (CBD) Nano Lipospheres
[0172] CBD nano lipospheres formulation was prepared by
pre-concentrate preparation method. The final nano lipospheres
composition was based on preliminary formulation optimization
studies and selected according to optimal solubilization capacity
of the active ingredient and smallest particle size obtained upon
dilution in aqueous phase. Prior to adding active ingredient, two
kinds of mixtures were prepared. The first is a mixture of
amphiphilic co-solvent (ethyl lactate) and phospholipid (lecithin)
at the ratio of 8:1, respectively. The second is a mixture of a
triglyceride (tricaprin), polyoxyl 40-hydroxy castor oil, Tween 20,
and Span 80 at the ratio of 1:1:1:1. Both mixtures were gently
stirred and heated to 40.degree. C. till homogenous solutions were
formed. Both mixtures were added at the ratio of 1:1 w/w to a clean
scintillation tube containing CBD powder, forming the CBD nano
lipospheres preconcentrate containing 3% CBD. This pre-concentrate
was gently stirred and heated to 40.degree. C. till homogenous
solution was formed. Upon gentle agitation in aqueous phase, this
pre-concentrate spontaneously forms drug encapsulated O/W
nanoemulsion. CBD solution in Propylen Glycol/EthOH/Water 30/30/40
respectively was used as control throughout all in-vivo
studies.
Characterization of the Formulations
[0173] The mean particles diameter, zeta potential and
polydispersity index of the formed formulations by 1:10 dilution of
the pre-concentrate in water are listed in Table 3. Amiodarone HCL,
talinolol, tacrolimus, CBD and blank formulations were administered
to animals by 1:10 dilution of the pre-concentrate in water. Thus,
the characterizations were AM assessed following this dilution.
TABLE-US-00004 TABLE 3 The mean particles diameter, zeta potential
and polydispersity index of the formed formulations by 1:10
dilution of the pre-concentrate in water Zeta potential Formulation
Size (d nm) (mv) Pdi Amiodarone 10 35.2 0.48 HCL CBD 26 0.07
Talinolol 45 5.9 0.45 Blank 52 13.2 0.38
Drug Release Studies
[0174] Soft gelatin capsules containing AM nano-liposheres (0.5 g)
were assessed for in-vitro release using standard USP 24 method,
apparatus II (paddles) equipment (Caleva ST7, G.B. Caleva Ltd.,
Dorset, UK). A stirring speed of 75 rpm was used at 37.degree. C.
in 500 ml of release medium (either pH 6.8 or pH 1.2). At
predetermined time points samples of the release medium (0.5 mL)
were withdrawn and analyzed by HPLC (analytical methods section)
for AM content. Gastric buffer pH 1.2 was prepared as following:
250 ml of NaCL 0.2M were mixed with 425 ml of HCL 0.2M then
distilled water was added to make a total volume of 1 L. Duodenal
buffer pH 6.8 was prepared as following: 112 ml of NaOH 0.1 M were
mixed with 250 ml of potassium dehydrogenphosphate then distilled
water was added to make a total volume of 1 L.
Emulsification Time Study
[0175] To assess the self-emulsification properties, the
emulsification time of the pro nanolipospheres was evaluated
according to United States Pharmacopeia (USP) XXIII, dissolution
apparatus II (Caleva ST7, G.B. Caleva Ltd., Dorset, UK). Briefly,
0.5 mL of the pro nano-lipospheres was added drop wise to 500 mL of
distilled water at 37.degree. C. Gentle agitation was provided by a
standard stainless steel dissolution paddle rotating at 50 rpm. The
emulsification time was visually assessed as previously
reported.
Emulsification Time and Drug Release Results
[0176] In both tested pH environments, pro nano-lipospheres
presented similar dissolution profile, where the drug was entirely
released within about 10 minutes (FIG. 1). The emulsification time
obtained for pro nano-lipospheres was .about.10 sec.
In-Vivo PK Studies
[0177] Animals: Male Wistar rats weighing 300-350 g were used for
the in vivo PK and ex vivo permeability studies. The project
adhered to the principles of Laboratory Animal Care. All animals
were deprived of food but not water 12 h prior to the experiments.
All surgical and experimental procedures were reviewed and approved
by the Animal Experimentation Ethics Committee of the Hebrew
University Hadassah Medical School Jerusalem. An indwelling cannula
was placed in the right jugular vein of each animal for systemic
blood sampling, by a method described by Hoffman, A. and G. Levy.,
J. Pharmacol Exp Ther., 249(1):117-22, 1989.
Amiodarone (AM) Bioavailability Studies
[0178] AM nano-lipospheres were freshly prepared 30 min before each
experiment, by vortex-mixing 1 mL of the pre-concentrate in 9 mL
water pre-heated to 37.degree. C. for 30 sec. The obtained AM
concentration was 3 mg/mL. AM nano-lipospheres (12.5 mg/kg) were
administered to the animals by oral gavage (n=6). The control group
received 12.5 mg/kg AM solution prepared from Amiodacore.RTM.
ampoules content (AM 50 mg/mL) dissolved in water to obtain 5 mg/mL
concentration (n=6). Systemic blood samples (0.35 mL) were taken at
5 min pre-dose, 0.5, 1, 2, 4, 8, 12, 24, 36 and 48 h post-dose.
[0179] For tacrolimus bioavailability studies, tacrolimus
nano-lipospheres were freshly prepared 30 min before each
experiment, by vortex-mixing 1 ml of the pre-concentrate in 9 ml
water pre-heated to 37.degree. C. for 30 sec. The obtained
concentration was 0.5 mg/ml. tacrolimus nano-lipospheres (1 mg/kg)
were administered to the animals by oral gavage (n=6). The control
group received 1 mg/kg tacrolimus suspension prepared from
Prograf.RTM. capsules content suspended in water to obtain 0.5
mg/ml concentration (n=6). Systemic blood samples (0.3 ml) were
taken at 5 min predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 8, and 12 h
post-dose.
[0180] For talinolol relative bioavailability studies:
nano-lipospheres were freshly prepared 30 min before each
experiment, by vortex-mixing of the pre-concentrate in water (1:9)
pre-heated to 37.degree. C. for 30 sec. The obtained talinolol
concentration was 1 mg/mL. Talinolol nano-lipospheres (4 mg/kg)
were administered to the animals by oral gavage (n=6). The control
group received 4 mg/kg talinolol dissolved in PEG400:water:ethanol
25:60:15 to obtain 1 mg/mL concentration (n=6).
[0181] For CBD relative oral bioavailability studies, nano
lipospheres was freshly prepared 30 min before each experiment, by
vortex-mixing of the pre-concentrate in water (1:9) pre-heated to
37.degree. C. for 30 sec. The obtained CBD concentration was 3
mg/mL. CBD nano lipospheres (15 mg/kg) was administered to the
animals by oral gavage (n=6). The control group received (15 mg/kg)
CBD solution in propylene glycol/EthOH/water 30/30/40 respectively
(1 mg/mL) (n=6).
[0182] Systemic blood samples (0.35 mL) were taken at 5 min
pre-dose, 20 min, 40 min, 1 h 1.3 h, 1.6 h, 2 h, 3 h and 4 h
post-dose.
AM PK Results
[0183] The plasma concentration time profiles for AM and AM-
nano-lipospheres following oral administration of dose equivalent
to 12.5 mg/kg AM are shown in FIG. 2. The corresponding AUC and
C.sub.max parameters obtained in these in vivo experiments are
listed in Table 4. The bioavailability of AM nano-lipospheres was
significantly greater in comparison to AM alone. Similar results
were obtained for the C.sub.max values.
[0184] Another finding is that the erratic absorption that
characterizes Amiodarone becomes more regular when the drug is
administered in the nano-formulation. The reduced fluctuations in
C.sub.max are of high importance since Amiodarone is characterized
by narrow therapeutic window and life-threatening side effects.
Reduction of such fluctuations may improve the safety of Amiodarone
therapy. In addition, the overall dose reduction which may be
achieved by higher bioavailability might result in reduction of
side effects of this drug.
Tacrolimus PK Results
[0185] The tacrolimus concentration vs. time plot following oral
administration of the drug alone or compounded in nano-lipospheres
(1 mg/kg) is presented in FIG. 3, and the derived PK parameters are
presented in Table 6.
[0186] The bioavailability of tacrolimus nano-lipospheres was
significantly greater in comparison to tacrolimus alone. Similar
results were obtained for the C.sub.max values.
[0187] Table 5 clearly demonstrates the reduced variability in
plasmas tacrolimus concentrations obtained following
tacrolimus-nano-lipospheres administration. Table 5 represents the
coefficient of variation (% CV) in various time points during two
hours following administration.
TABLE-US-00005 TABLE 4 PK parameters derived from PO administration
of tacrolimus and tacrolimus-SNEDDS 1 mg/kg (n = 5 for each group).
*Significant difference (p < 0.05) from tacrolimus corresponding
value is found. Cmax (ng/mL) AUC (hr*/ng/mL) 14.7 .+-. 4/11 40.8
.+-. 10.6 tacrolimus 23.8 .+-. 2.66(*) 69.4 .+-. 8.96(*)
Tacrolimus-nano lipospheres
TABLE-US-00006 TABLE 5 Coefficient of variation (% CV) in various
time points during two hours following oral administration of
tacrolimus and tacrolimus- nano-lipospheres 1 mg/kg (n = 5 for each
group). * Significantly lower % CV than the corresponding values at
the same time point in the group that received tacrolimus alone.
tacrolimus tacrolimus-nano-lipospheres time (h) 95.1 31.5 (*) 0.25
90.8 35.8 (*) 0.5 73.2 9.1 (*) 0.75 83.5 22.0 (*) 1 70.5 30.7 (*)
1.5 103.5 45.4 (*) 2
[0188] These findings demonstrate that Amiodarone and tacrolimus
bioavailability increases not only when it is encapsulated in
nano-lipospheres, but even the simultaneous presence of empty (i.e.
drug-less) nano-lipospheres in the intestine. Moreover,
encapsulation into nano-lipospheres reduces the high variability in
plasma concentrations, typical for Amiodarone, tacrolimus and other
BCS class II compounds.
CBD PK Results
[0189] The plasma concentration time profiles for CBD and CBD nano
lipospheres following oral administration of 15 mg/kg CBD to rats
are shown in FIG. 3. The corresponding AUC and C.sub.max parameters
obtained in these in vivo experiments are listed in Table 6.
[0190] The bioavailability of CBD nano lipospheres was
significantly greater in comparison to CBD alone. Similar results
were obtained for the Cmax values.
TABLE-US-00007 TABLE 6 PK parameters derived from PO administration
of CBD and CBD nano lipospheres 15 mg/kg (n = 6 for each group). *
Significant difference (p < 0.05) fromCBD corresponding value is
found AUC (min * ng/mL) C.sub.max (ng/mL) 15533 .+-. 11679 105 .+-.
103 CBD 46356 .+-. 14567(*) 337 .+-. 100 (*) CBD
nano-lipospheres
[0191] Thus, incorporation of CBD into nano lipospheres is a
promising strategy to overcome major obstacles in the way of
development oral treatments with CBD such as first pass hepatic
metabolism, instability in the acidic gastric pH and/or low water
solubility, leading to incomplete absorption
Talinolol PK Results
[0192] Significantly higher plasma talinolol concentrations were
obtained following talinolol nano lipospheres administration in
comparison to free talinolol (FIG. 4). Corresponding increase in
AUC and C.sub.max values are shown in Table 7.
TABLE-US-00008 TABLE 7 Summary of PK parameters derived from PO
administration of talinolol vs. talinolol nano-liposheres at the
dose of 4 mg/kg (n = 5 for each group). Talinolol nano- Talinolol
lipospheres 11.9 .+-. 2.71 (*) 35.98 .+-. 8.09 AUC (Hr * ng/mL)
5.55 .+-. 1.65 15.28 .+-. 4.7 C.sub.max (ng/mL) 1.15 .+-. 0.19 1.31
.+-. 0.23 T.sub.1/2 (hr)
[0193] Based on this finding we conclude that nano-lipospheres
possess the ability to inhibit intestinal P-gp efflux and thus to
increase the oral bioavailability of intra enterocyte P-gp efflux
substrates upon oral administration.
AM Tissue Distribution Studies
[0194] The rats were randomly assigned into two groups (n=3 in each
group) and received AM or AM nano-lipospheres (12.5 mg/kg) for 5
days, once daily by oral gavage. Two hours after the last dose the
rats were euthanized by CO.sub.2 and liver and heart were removed
and weighted. Plasma samples were collected as well.
[0195] The tissue distribution results (FIG. 5) corroborate the
increased plasma AUC obtained following single AM nano-lipospheres
administration. Following chronic oral administration of AM
nano-lipospheres and AM, we observed increased tissue (heart and
liver) and corresponding plasma concentrations of AM in the AM
nanolipospheres group. Interestingly, the extent of increase was
similar in both tissues and plasma (about 1.5 folds). Since AM has
a high volume of distribution and is extensively bound to tissues,
the correlation between single and multiple dosing results
emphasizes that the enhanced bioavailability of AM nano-lipospheres
is a constant and profound effect.
Blank Nano Lipospheres Co-Administration Studies
[0196] For the assessment of blank nano-lipospheres
co-administration effect on AM bioavailability, blank
nano-lipospheres not containing AM were freshly prepared as
described above and administered by oral gavage. AM
(Amiodacore.RTM.) was administered immediately after that by the
same route (n=6). The blank nanolipospheres volume was equal to AM
nano-lipospheres volume administered in the bioavailability studies
and the AM dose was 12.5 mg/kg (approximately 150 .mu.l of 25 mg/mL
AM solution).
[0197] For assessment of blank nano-lipospheres co-administration
effect on AM nano-lipospheres bioavailability, AM nano-lipospheres
were prepared as described above and administered by oral gavage.
The administered dose was 12.5 mg/kg (n=6). Blank nano-lipospheres
were freshly prepared and 1 mL was administered by the same route.
Systemic blood samples (0.35 mL) were taken at 5 min pre-dose, 0.5,
1, 2, 4, 8, 12, 24, 36 and 48 h post-dose. To prevent dehydration
equal volumes of physiological solution were administered to the
rats following each withdrawal of blood sample. Plasma was
separated by centrifugation (4000 g, 7 min, 4.degree. C.) and
stored at -20.degree. C. pending analysis (FIGS. 6A-D).
Blank Nano Lipospheres Co-Administration Results
[0198] The bioavailability of AM nano-liposheres, AM+blank
nano-liposheres, and AM nano-liposheres+blank nano-liposheres was
significantly greater in comparison to AM alone. Similar results
were obtained for the Cmax values. Moreover, the AUC value
following AM nano-liposheres+blank nano-liposheres administration
was significantly higher than other delivery systems. There was no
significant difference found between the obtained AUC and Cmax
values following AM nano-liposheres and AM+blank nano-liposheres
administration. These results demonstrate that co-administration of
blank nano-liposheres with the drug has the same effect on its
bioavailability as the incorporation into the nano-liposheres.
TABLE-US-00009 TABLE 8 Summary of PK parameters derived from PO
administration of AM, AM nano- liposheres, AM + blank
nano-liposheres and AM- nano-liposheres + blank nano- liposheres in
the dose of 12.5 mg/kg (n = 5 for each group). * Significant
difference (p < 0.05) from amiodarone corresponding value is
found. .dagger. Significant difference (p < 0.05) from
(amiodarone + blank nano-liposheres) and (nano-liposheres + Blank
nano-liposheres) corresponding value is found AM nano- liposheres +
AM + AM blank nano- blank nano- AM nano-lipospheres lipospheres
lipospheres AUC 4.54 .+-. 2.6 9.52 .+-. 0.47 (*) 13.0 .+-. 4.78
(*.dagger.) 10.65 .+-. 4.38 (*) (hr * .mu.g/ml) Cmax 0.36 .+-. 0.07
0.66 .+-. 0.08 1.32 .+-. 0.54 (*.dagger.) 0.73 .+-. 0.16 (*)
(.mu.g/mL) T1/2 (hr) 11.3 .+-. 4.26 18.0 .+-. 5.41 16.6 .+-. 6.36
12.3 .+-. 2.21 V/F (mL/kg) 34320 .+-. 5447 33774 .+-. 8638 24421
.+-. 8099 22451 .+-. 4950 CL/F 2412 .+-. 1428 1315 .+-. 66.3 1061
.+-. 396 1309 .+-. 454 (mL/hr/kg) F (%) 23.66 49.60 (*) 67.96 (*)
55.50 (*)
[0199] Absolute bioavailability (F) values were calculated using
the following equation
F = AUC iv * Dose po AUC po * Dose iv ##EQU00001##
and utilizing the AM AUC.sub.iv values from our preliminary IV
studies.
[0200] In addition, the absolute CL values were back calculated by
multiplying the CL/F obtained for each group by its corresponding F
value calculated as described above. No significant difference was
found between the CL values of the different study groups and the
CLiv value from our preliminary study, implying that
nano-liposheres administration did not affect AM clearance rate and
extent.
Investigation of Duration of Nano-Lipospheres Effect on GI
Absorption and Enterocyte Recovery
[0201] Freshly prepared as described above blank nano-lipospheres
were administered by oral gavage. The blank nano-lipospheres volume
was equal to AM nano-lipospheres volume administered in the
bioavailability studies. After 2 hours 12.5 mg/kg AM solution
prepared from Amiodacore.RTM. ampoules content as described above
was administered (n=3). The control group received 12.5 mg/kg AM
solution prepared from Amiodacore.RTM. ampoules at the same time
point (n=3). In the investigation of duration of nano-lipospheres
effect on GI absorption of AM, the last sampling point was 12
hours, assuming the effect will not last beyond this stage.
Duration of Nano-Liposheres Effect on GI Absorption and Enterocyte
Recovery Results
[0202] The plasma concentration time profiles for AM following oral
administration at a dose of 12.5 mg/kg 2 hours after administration
of blank nano-lipospheres or water are shown in FIG. 7. There was
no significant difference in the obtained AM plasma concentrations
between the groups. These results suggest that the effect of
nano-lipospheres on AM bioavailability is reversible and lasts no
more than 2 hours.
AM Pharmacodynamic (PD) Study
[0203] Most of the investigations described so far have evaluated
the pharmacokinetics of the drug when incorporated in lipospheres
and very few investigations have demonstrated pharmacodynamic
efficacy. Although pharmacokinetic studies are sufficient to
establish proof of concept for lipospheres, the results of the
pharmacokinetic study should preferably be corroborated by
pharmacodynamic studies. This is particularly important for drugs
which do not show pharmacokinetic-pharmacodynamic correlation. Such
aspects should be carefully considered while planning
investigations on the lipospheres.
[0204] Bradicardia and hypotension have been reported as the most
common haemodynamic effects caused by acute AM administration.
Several studies assessed the effect of AM on heart rate in freely
moving rats using radiotelemetry method following IV and PO AM
administration. Radiotelemetry is the "state of the art" for
monitoring physiological functions in awake and freely moving
animals, while minimizing stress artifacts and effects of
anesthesia.
[0205] Da Silva et al. (Am J Physiol Regul Integr Comp Physiol.,
283(2):R543-8m 2002) reported a significant increase in R-R
interval 5 min post AM IV administration (50 mg/kg). Such
bradicardia, observed in several studies following single high IV
AM dose can be attributed to several mechanisms; for instance,
Na.sup.+ and Ca.sup.2+ channel blocking actions depressing the
automaticity of sinus node, a non-competitive beta-adrenoreceptor
blockade, a reserpine like sympatholytic action and direct K.sup.+
channel blockade. In contrast, a lower AM dose (25 mg/kg) triggered
a brief tachycardia, indicating that only higher AM dose was able
to counteract the baroreflex allowing the reflex tachycardia to
occur.
[0206] The deferential effect of AM on heart rate was used as a
pharmacodynamic marker for assessment of AM pharmacological effect
following oral administration.
Transmitter Implantation
[0207] Male Wistar rats (Harlan, Israel) weighing 300-350 g were
kept under a 12 h light/dark cycle with free access to water and
food (standard rat chow) Animals were anesthetized for the period
of surgery by intraperitoneal injection of 1 mL/kg of
ketamine-xylazine solution (90/10%, respectively).
[0208] An ECG transmitter (TA11CA-F40, Data Sciences International
Inc., St. Paul, Minn.) was implanted subcutaneously over the
scapula with the leads in a Lead 2 configuration by tunneling
subcutaneously from the dorsal incision using a trocar. The
negative lead was placed in the area of the right shoulder and the
positive lead was placed immediately to the left of the xyphoid
space and caudal to the rib cage.
[0209] After the surgery the animals were left to recover for 5
days. During the first 72 hours of the recovery period the animals
were treated with Bitryl (5 mg/kg) and Tramadol (5 mg/kg).
Data Recording and Analysis
[0210] A night before the recording the animals were relocated in
their cages to the recording room in order to adjust to the new
environment. The experiment started after the animals were at least
8 hours with food deprivation.
[0211] The signal from the transmitters was received by two RLA
2000 receivers and transmitted via a Data Exchange Matrix to a
Dataquest PCI card. The data were recorded continuously during the
whole experiment at 1000 Hz rate with no filter cutoff and full
scale at 10 mV.
[0212] The collected data were interpreted by Dataquest A.R.T
program. The IBI (R-R duration, sec) and HR (bpm) were calculated
in average values of each 10 min of the recording.
[0213] At the beginning the baseline were recorded at least for 120
min After establishing stable recording the rats were treated by
oral gavage. During the treatment the data was collected and
afterwards extracted in further analysis.
Dosing Protocol
[0214] Two groups of three rats received the treatment in a cross
over manner, meaning each rat received each treatment once. The
treatments were as follows:
[0215] AM: 12.5 mg/kg AM solution prepared from Amiodacore.RTM.
ampoules content (AM 50 mg/mL) dissolved in water to obtain 2.5
mg/mL concentration
[0216] AM nano-lipospheres: AM containing nano-lipospheres were
freshly prepared 30 min before each experiment, by vortex-mixing of
the pro nano-dispersion containing AM in water (1:9) pre-heated to
37.degree. C. for 30 sec. The obtained AM concentration was 3
mg/mL. The AM nano-lipospheres (12.5 mg/kg) were administered to
the animals by oral gavage.
[0217] After each recording phase the rats were left for the
washout period of 7 days before the next recording phase.
[0218] AM+Blank Lipospheres: Blank nano-lipospheres not containing
AM was freshly prepared as described above and was administered by
oral gavage. AM (Amiodacore.RTM.) was administered immediately
after that by the same route. The blank nano-lipospheres volume was
equal to AM nano-lipospheres volume administered in to the AM group
and the dose was 12.5 mg/kg identical.
[0219] Blank nano-lipospheres with AM nano-lipospheres: AM-
nano-lipospheres were prepared as described above and was
administered by oral gavage. The administered dose was 12.5 mg/kg.
Blank nano-lipospheres were freshly prepared and 1 mL was
administered by the same route.
[0220] Sham group received equivalent volume of nano-liposphere
without any active ingredient.
[0221] After each recording phase the rats were left for the
washout period of 7 days before the next recording phase.
Pharmocodynamic Results
[0222] One week following transmitter implantation all animals did
not exhibit significant changes of body weight as compared to the
pre-surgery status. A normal behavioral pattern was observed 48-72
hours after the surgery, including circadian rhythm, grooming,
exploration of the cage and reactivity to handling.
[0223] Initially, baseline recording were performed in order to
obtain the signal pattern and to assure that the ECG leads were
stable at their insertion points. ECG signals were not filtered or
smoothed neither during the recording session nor during analysis.
All of the animals showed fine signal strength and ECG wave
pattern. The recording yielded adequate R wave amplitudes and QRS
complexes for determinations of heart rate (HR) and intra-beat R-R
interval (IBI) variability.
[0224] In order to inspect separately the effect of each delivery
method, we first calculated the mean baseline IBI duration
throughout 60 min prior the administration. The drug was
administered at t=60 min Post administration the data was
calculated throughout 180 min. The net change was calculated as the
percentage of the change for each drug administration mode relative
to the baseline recording. The changes from base-line in two
parameters: IBI and HR were analyzed in two points: 90 min post
administration (mid phase) and 180 min post administration (end
phase) (Tables 9A-B and 10A-B, respectively).
[0225] Sham operated group that received only the blank
nano-lipospheres without any active compound, didn't exhibit any
significant change in the IBI duration and HR.
[0226] Following AM (12.5 mg/kg) administration, the mean IBI
values decreased from 0.175.+-.0.006 sec to 0.143.+-.0.0074 sec and
the heart change increased 344.+-.13.58 BPM to 452.916.+-.20.01 as
expected.
[0227] When the drug was incorporated into the nano-lipospheres (AM
nano-lipospheres) the mean IBI increased from 0.179.+-.0.0026 sec
to 0.197.+-.0.009 sec and the heart rate decreased from
390.9.+-.9.4 BPM to 365.334.+-.7.089 BPM. Thus, at same when the
drug at the same dosage was incorporated into the nano-lipospheres,
a reverse effect was shown. This effect, bradycardia, of the drug
is characteristic to the high dosage of AM meaning that the drug
incorporation to the nano-lipospheres increases the bioavailability
of the drug and the drug concentrations at the active site (cardiac
tissue). Similar bradycardic effect was created when AM was
co-administered with blank nano-lipospheres (AM+Blank
nano-lipospheres): the mean IBI increased from 0.175.+-.0.002 sec
to 0.184.+-.0.003 sec and the HR decreased from 377.54.+-.4.82 BPM
to 342.522.+-.13.94 BPM (FIGS. 8 and 9).
TABLE-US-00010 TABLE 9 Mean HR (A) and IBI (B) changes (as
percentage from baseline) following 12.5 mg/kg AM following
administration in 3 different formulations: AM, AM nanolipospheres
(SNEDDS), AM + Blank nano lipospheres and administration of blank
nanolipospheres, as measured at the mid phase (90 min following
oral administration) A. HEART RATE (BPM) CHANGE % BASELINE MID
PHASE 131.28 452.916 .+-. 20.01 344 .+-. 13.58 AM 93.46 365.334
.+-. 7.089 390.9 .+-. 9.4 AM SNEDDS 90.73 342.522 .+-. 13.93 377.54
.+-. 4.82 AM+ BLANK SNEDDS 105.72 354.605 .+-. 18.43 335.42 .+-.
12.89 SHAM END PHASE 128.43 443.071 .+-. 11.06 344 .+-. 13.58 AM
95.37 372.839 .+-. 11.54 390.9 .+-. 9.4 AM SNEDDS 92.61 349.626
.+-. 8.00 377.54 .+-. 4.82 AM+ BLANK SNEDDS 106.09 355.870 .+-.
11.63 335.42 .+-. 12.9 SHAM B. IBI (sec) CHANGE % BASELINE MID
PHASE 88.86 0.1435 .+-. 0.008 0.175 .+-. 0.006 AM 110.01 0.197 .+-.
0.009 0.179 .+-. 0.0026 AM SNEDDS 104.04 0.182 .+-. 0.003 0.175
.+-. 0.002 AM + BLANK SNEDDS 98.57 0.173 .+-. 0.01 0.175 .+-. 0.001
SHAM END PHASE 89.79 0.143 .+-. 0.007 0.175 .+-. 0.006 AM 108.76
0.195 .+-. 0.008 0.179 .+-. 0.0026 AM SNEDDS 105.39 0.184 .+-.
0.003 0.175 .+-. 0.002 AM + BLANK SNEDDS 98.39 0.172 .+-. 0.01
0.175 .+-. 0.001 SHAM
TABLE-US-00011 TABLE 10 Mean HR (A) IBI (B) and changes (as
percentage from baseline) following 12.5 mg/kg AM following
administration in 3 different formulations: AM, AM nanolipospheres,
AM + Blank nano lipospheres and administration of blank
nanolipospheres, as measured at the end phase (180 min following
oral administration). A. HEART RATE (BPM) CHANGE % BASELINE MID
PHASE 131.28 (*) 452.916 .+-. 20.01 344 .+-. 13.58 AM 93.46 (*)
365.334 .+-. 7.089 390.9 .+-. 9.4 AM SNEDDS 90.73 (*) 342.522 .+-.
13.94 377.54 .+-. 4.82 AM + BLANK SNEDDS 105.72 354.605 .+-. 18.43
335.42 .+-. 12.89 SHAM END PHASE 128.43 (*) 443.07 .+-. 11.06 344
.+-. 13.58 AM 95.37 (*) 372.839 .+-. 11.54 390.9 .+-. 9.4 AM SNEDDS
9.61 (*) 349.626 .+-. 8.00 377.54 .+-. 4.82 AM + BLANK SNEDDS
106.09 355.870 .+-. 11.63 335.42 .+-. 12.89 SHAM B. IBI (sec)
CHANGE % BASELINE MID PHASE 88.86 (*) 0.1435 .+-. 0.008 0.175 .+-.
0.006 AM 110.01 (*) 0.197 .+-. 0.009 0.179 .+-. 0.0026 AM SNEDDS
104.04 (*) 0.182 .+-. 0.003 0.175 .+-. 0.002 AM + BLANK SNEDDS
96.57 0.173 .+-. 0.01 0.175 .+-. 0.001 SHAM END PHASE 89.79 (*)
0.143 .+-. 0.007 0.175 .+-. 0.006 AM 108.76 (*) 0.195 .+-. 0.008
0.179 .+-. 0.0026 AM SNEDDS 105.39 (*) 0.184 .+-. 0.003 0.175 .+-.
0.002 AM + BLANK SNEDDS 98.39 0.172 .+-. 0.01 0.175 .+-. 0.001
SHAM
[0228] These findings demonstrate that Amiodarone bioavailability
increases not only when it is encapsulated in nano-lipospheres, but
even the simultaneous presence of empty (i.e. drug-less)
nano-lipospheres in the intestine. Moreover, encapsulation into
nano-lipospheres reduces the high variability in plasma
concentrations, typical for amiodarone and other BCS class 2
compounds. Our PD studies results corroborate the PK findings and
demonstrate similar PD effect upon administration of AM
nano-lipospheres and AM+blank nano-lipospheres, which is
significantly different from the PD effect obtained upon
administration of free AM.
Parenteral Administration of the Nano-Lipospheres
[0229] As for IV administration, the nano-liposphere formulation
alters the biodistribution parameters of a given molecule, as well
as its disposition. FIG. 10 demonstrates the plasma
concentration-time profile obtained following IV administration of
12.5 .mu.g/kg Amiodacore.RTM. and AM nano-lipospheres. It can be
seen that the administration of nano-lipospheres resulted in higher
plasma concentrations of AM at the central compartment during the
first disposition phase. The AUCs were 22.1 and 17.1 .mu.g/mL after
AM nano-lipospheres and Amiodacore.RTM. administration
respectively.
[0230] It can be seen that the nano-lipospheres also alter the PK
parameters of the administered drug. Significant reduction in
volume of distribution and in clearance of amiodarone when
administered as nano-lipospheres are observed (Table 11). The
reduction in Vss is a result of better solubility of the drug in
plasma while encapsulated in nano-lipospheres. Thus, more drug is
retained in the central compartment. As drug encapsulated in the
formulation reaches P-gp containing barriers (such as the
blood-brain barrier), it might possess improved penetration
qualities due to the P-gp inhibition ability of the formulation. As
a result, penetration of parenteral drugs to P-gp expressing
tissues will be improved.
TABLE-US-00012 TABLE 11 PK parameters obtained following IV
administration of 12.5 .mu.g/kg Amiodacore .RTM. and AM
nano-lipospheres. HL Cl (mL/hr(kg) Vss (mL/kg) AUC (hr * ug/mL) (h)
549 8002 22.9 17.1 nano- lipospheres 818 18138 15.3 22.1
Amiodacore
In-Vitro Mechanistic Investigation
In Vitro Permeability Studies Using Caco-2 Cells:
[0231] Caco-2 cell line is a broadly used in vitro model to study
various aspects of intestinal permeability of drug molecules, which
was established by Fogh in 1974. The Caco-2 cell line is derived
from a human colon carcinoma. These cells spontaneously
differentiate to enterocytes under conventional cell culture
conditions. Caco-2 cells exhibit morphological as well as
biochemical similarities to intestinal (absorptive) enterocytes.
The cells form tight intercellular junctions and microvilli,
express several transporters (e.g. sugar carrier, bile acid
carrier, large neutral amino acid carrier, and P-gp) and metabolic
enzymes (e.g. aminopeptidases, esterases, sulfatases, and
cytochrome P450 enzymes). The unusually high degree of
differentiation, morphological and functional structure resembling
enterocytes has resulted in Caco-2 becoming one of the most popular
cell culture models to study intestinal epithelial integrity and
drug transport.
[0232] For determination of nano-lipospheres ability to inhibit
intestinal P-gp efflux pumps, Caco-2 transport study was performed
using talinolol as a model molecule. As previously stated,
talinolol is a known P-gp substrate and is not metabolized by the
intra-enterocyte CYP enzymes. In this case, the donor compartment
of the transwells contained either 10 .mu.g/mL talinolol, or 10
.mu.g/mL talinolol with blank nanolipospheres (amount equivalent to
100 .mu.g/mL AM- nano lipospheres). At fixed time points (0, 30,
60, 90, 120, and 150 min), 150 .mu.L samples were withdrawn from
the receiver side, and similar volumes of blank buffer were added
to maintain constant volume. C14-Mannitol, a commonly used marker
for passive paracellular permeability, was used for further
evaluation of proper carrying out of each study.
[0233] In-vitro permeability studies of talinolol through Caco-2
monolayers resulted in significantly higher (p<0.001)
permeability coefficient values of talinolol+blank nano-lipospheres
vs. talinolol (1.73.times.10-6 and 7.66.times.10-7 respectively) in
A to B direction. As expected for P-gp substrate, both talinolol
and talinolol+blank nano-lipospheres Papp values obtained in the B
to A direction are higher than the corresponding Papp values
obtained in the A to B direction. B to A permeability resulted in
statistically significant (p<0.001) reduction in Papp values
obtained for talinolol+blank nano-lipospheres vs. talinolol
(7.36.times.10-6 and 1.77.times.10-5 respectively), as expected for
P-gp substrate when P-gp activity is inhibited (FIG. 11).
[0234] It should be emphasized that talinolol was not incorporated
into nano-lipospheres, but administered simultaneously. These
results suggest that nano-lipospheres possess the ability to
inhibit P-gp efflux and thus to increase the oral bioavailability
of compounds subjected to extensive intra-enterocyte efflux.
Furthermore, nano-lipospheres can inhibit P-gp not only by
incorporation of the compound into this delivery system but also
when nano-lipospheres e.g. blank nano-lipospheres are administered
simultaneously with the active compound. As expected for a P-gp
substrate, both values obtained in the basal-to-apical direction
are higher than the Papp obtained in the apical-to-basal direction.
Interestingly, basal-to-apical permeability resulted in significant
reduction in Papp values obtained for talinolol-nano lipospheres
vs. talinolol. This pattern is typical for P-gp substrates in the
presence of a P-gp inhibitor; while apical-to-basal efflux is
increased due to P-gp inhibition, the opposite direction transport
is decreased as a result of reduced P-gp contribution to drug
transport from the enterocyte to the lumen.
[0235] To comprehend the effects of nano-lipospheres on
intra-enterocyte metabolic activity, we tested its effect on CYP3A4
mediated AM and testosterone (control CYP 3A4 substrate) metabolism
in isolated rat CYP 3A4 microsomes (FIG. 12). Significant
difference (p<0.01) was found between intact AM concentrations
remaining following 120 min incubation of AM- nano-lipospheres vs.
AM (102.4.+-.5.61% and 68.57.+-.1.17% respectively). In order to
distinguish between mechanistic protection of nano-lipospheres from
enzymatic degradation and the effect of nano-lipospheres
ingredients on enzymatic activity, blank nano-lipospheres were
added to testosterone and incubated in microsomes. Significant
difference (p<0.05) was found between testosterone with
nano-lipospheres vs. testosterone alone incubated at the same
conditions (91.26.+-.5.31% and 75.39.+-.8.82% respectively).
[0236] These results imply that increased bioavailability achieved
by nano-lipospheres partially results from reduced first pass
intra-enterocyte metabolism. Moreover, similarly to our in vivo
results, the incorporation of the drug into nano-lipospheres was
not necessary to gain the effect of increased bioavailability or
reduced first pass metabolism, and co-administration of the drug
with the blank nano-lipospheres resulted in comparable effects.
Safety and Toxicity Studies
In-Vitro Paracellular Transport Studies:
[0237] Caco-2 cells permeability studies were performed with
paracellular transport marker C14-Mannitol (2 .mu.Ci/mL). Samples
(200 .mu.L) were withdrawn from the basolateral side at the same
fixed time points described above, and similar volumes of blank
buffer were added following each withdrawal.
Transepithelial Electrical Resistance (TEER) Studies:
[0238] Caco-2 cells were grown on 12-transwell plate and cultured
for 21 days. The apical buffer was replaced with 0.6 mL pre-warmed
(37.degree. C.) apical buffer containing blank nano-lipospheres
(amount equivalent to 100 .mu.g/mL AM- nano-lipospheres). In order
to evaluate the effect of the nano-lipospheres on the paracellular
transport across the cells (i.e. the extent to which the tight
junctions are opened), TEER values were measured at the above time
points and compared to the TEER values measured in control cells
containing only buffer.
[0239] In FIG. 13, the outer line represents the TEER values of
Caco-2 monolayers in the presence of blank nano-lipospheres or
control. There was no difference in the TEER values measured
throughout the experiment both in the presence and absence of blank
nano-lipospheres (p=0.19), indicating that the integrity of the
monolayer was remained. The embedded chart represents the Papp
values of mannitol (a paracellular transport marker) following
incubation with blank nano-lipospheres or control in Caco-2 model.
There was no significant difference in the permeability of mannitol
in the presence of blank nano-lipospheres compared to buffer
(p=0.51). These observations indicate that nano-lipospheres neither
affect paracellular permeability, nor disrupt the enterocyte
monolayer integrity.
Cellular Toxicity Studies:
[0240] Lactate dehydrogenase (LDH) is a cytoplasmic enzyme which is
released into the culture supernatant when the plasma membrane is
damaged. Nano-lipospheres toxicity was assessed over a range of
concentrations (0.1, 1, 5, and 10% in medium) in Coco-2 cells grown
as described above using LDH cytotoxicity detection kit, after the
incubation of the cell culture with blank nano-lipospheres
containing medium for 2 h. Percent of cell damage is calculated so
that low control was the spontaneous LDH release measured in
untreated cells medium and high control was 100% LDH release
measured in cells incubated with 1% Triton X-100 containing
medium.
[0241] As shown in FIG. 14, nano-lipospheres increased LDH release
in concentration dependant manner with highest toxicity obtained at
10% nano-lipospheres concentration (7.27%) and negligible toxicity
(<1%) produce by nano-lipospheres concentration of 1% and less
compared to 100% toxicity standard. These results suggest that no
significant damage is caused to the apical cell membrane of the
enterocyte by nano-lipospheres administration. Moreover, an
overestimation of cytotoxicity might be obtained in Caco-2 model
since it is lacking the repair and recovery mechanisms present in
the intact tissue.
[0242] Thus, it is shown that nano-lipospheres improve oral
bioavailability of Class II compounds by multi-processes mechanism:
increased GI milieu solubilization, reduced intra-enterocyte
metabolism and reduced P-gp efflux activity. In addition to
increased bioavailability, nano-lipospheres reduces the high
variability typical for Class II compounds. Nano-lipospheres do not
cause tissue or cell membrane damage. Therefore, the present
invention further concerns a composition being the nano-lipo
formulation as described above, but devoid of a drug (`empty
composition) for oral administration for increasing the absorption
of a drug with low bioavailability due to first pass intestinal
metabolism or substrate of intestinal efflux transporters (e.g.
P-gp) administered simultaneously, or in a close time window to the
nano lipo formulation.
[0243] Based on these finding it is concluded that the
nano-formulation serve as a platform for administration of drugs
which are P-gp and CYP3A4 substrates that are characterized by low
oral bioavailability and erratic absorption. Examples of P-gp and
CYP3A4 substrates that are suitable candidates for administration
in nanolipospheres are listed in Table 12.
TABLE-US-00013 TABLE 12 Examples of P-gp and CYP3A4 substrates at
the gut-wall and the liver, which are suitable candidates for
administration in nano-lipospheres Amlodipine Calcium channel
blockers Diltiazem Felodipine Nicardipine Nifedipine Nimodipine
Nisoldipine Verapamil Cyclosporine when administered with
Immunosuppressants "empty" lipo-nanosphere formulation Sirolimus
Tacrolimus Atorvastatin Statins Lovastatin Simvastatin Fexofenadine
Antihustamins Buspirone CNS drugs Carbamazepine Pimozide Midazolam
Triazolam Albendazole Anti-fungal/antibiotics Itraconazole
Erythromycin Amiodarone Miscellaneous Cisapride Colchicine
Sildenafil
[0244] Moreover, nano lipospheres of the present invention affect
intestinal CYP3A4 enzyme in a reversible and non selective manner,
such that it is possible that the nano lipospheres of the present
invention inhibit other metabolic enzymes in the intestine e.g.
CYP2C19 and CYP2C9.
Cannabidiol and Cannabidiol-Piperine Nano-Liposphere Formation
(CBD-PNL and CBDpiperine-PNL, Respectively)
[0245] CBD nano lipospheres formulation was prepared by
pre-concentrate preparation method. The final nano-lipospheres
composition was based on preliminary formulation optimization
studies and selected according to optimal solubilization capacity
of the active ingredient. Initially amphiphilic co-solvent (ethyl
lactate) and phospholipid (lecithin) at the ratio of 8:1,
respectively were placed in a clean scintillation tube and heated
to 40.degree. C. until the lecithin was completely dissolved. Then
triglyceride (tricaprin), polyoxyl 40-hydroxy castor oil, Tween 20,
and Span 80 at the ratio of 1:1:1:1 were added; the mixture was
gently stirred and heated to 40.degree. C. till homogenous solution
was formed. Further, CBD powder was added, forming the CBD
preconcentrate containing 3% CBD. This pre-concentrate was gently
stirred and heated to 40.degree. C. till homogenous solution was
formed. Upon gentle agitation in aqueous phase, this
pre-concentrate spontaneously forms drug encapsulated
nano-dispersion. For the preparation of CBD-Piperine-PNL piperine
powder was added with CBD powder to form the CBD-Piperine-PNL. CBD
solution in Propylen Glycol/EthOH/Water 30/30/40 respectively was
used as control throughout all in-vivo studies.
In-Vivo PK Studies
[0246] Animals:
[0247] Male Wistar rats weighing 300-350 g were used for the in
vivo studies. The project adhered to the principles of Laboratory
Animal Care (NIH publication no. 85-23, revised 1985). All animals
were deprived of food but not water 12 h prior to the experiments.
All surgical and experimental procedures were reviewed and approved
by the Animal Experimentation Ethics Committee of the Hebrew
University Hadassah Medical School Jerusalem. An indwelling cannula
was placed in the right jugular vein of each animal for systemic
blood sampling.
[0248] CBD Relative Oral Bioavailability Studies,
[0249] Nano lipospheres was freshly prepared 30 min before each
experiment, by vortex-mixing of the pre-concentrate (CBD-PNL and
CBD-Piperine-PNL) in water (1:9) pre-heated to 37.degree. C. for 30
sec. The obtained CBD and piperine concentrations were 3 mg/mL and
2 mg/ml, respectively. CBD-Piperine-PNL (15 mg/kg of CBD and 10
mg/kg of piperine) was administered to the animals by oral gavage
(n=6). The control groups received (15 mg/kg) CBD solution in
propylene glycol/EthOH/water 30/30/40 respectively (1 mg/mL) (n=6)
or CBD-PNL ((15 mg/kg of CBD).
[0250] Systemic blood samples (0.35 mL) were taken at 5 min
pre-dose, 20 min, 40 min, 1 h 1.3 h, 1.6 h, 2 h, 3 h and 4 h
post-dose.
Results:
[0251] 1.1 The results indicate that in rats the Piperine-PNL
elevated the bioavailability of CBD by 6 fold (Table 13, FIG. 15).
The contribution of the Piperine component was 2 fold increased
bioavailability due to its phase-II metabolism inhibition.
TABLE-US-00014 TABLE 13 PK parameters (mean .+-. S.E.M.) derived
from PO administration of CBD, CBD-PNL and CBD-Piperine-PNL 15
mg/kg; Piperine 10 mg/kg (n = 6 for each group). (*) Significant
difference (p < 0.05) from CBD corresponding value is found
.dagger. Significant difference (p < 0.05) from (CBD) and
(CBD-PNL) corresponding value is found. AUC (h * ng/mL) Cmax
(ng/mL) 90 .+-. 21 39 .+-. 8 CBD 300 .+-. 95 (*) 137 .+-. 43 (*)
CBD-PNL 570 .+-. 23 (*.dagger.) 170 .+-. 13 (*)
CBD-Piperine-PNL
[0252] Currently, there are limited pharmaceutical solutions in the
clinical setting to overcome the absorption barriers accounted for
poor oral drug availability. As mentioned hereinabove, "First pass
metabolism" (both by Phase I and Phase II enzymes at the enterocyte
level) and efflux transporters; P-gp hamper the oral delivery of
many drugs. PNL previously developed by our group have been
successfully utilized to enhance the oral absorption of drugs
subjected to intraenterocyte Phase I "first-pass" metabolism and
P-gp efflux. The innovation of our current approach is adding
piperine into PNL.
[0253] The utilization of piperine in addition to PNL
synergistically enhances bioavailability and may increase the oral
absorption to greater extent than the utilization of PNL alone. The
result is a platform that can be employed for: [0254] 1. Drugs
which are subjected to Phase I intra-enterocyte metabolism and/or
P-gp efflux. [0255] 2. Various drugs which are also directly
eliminated by phase II metabolism e.g. glucuronidation process.
[0256] Thus, the present invention applies the Piperine-PNL concept
to compounds suffering from significant first pass Phase I, phase
II metabolism and/or P-gp efflux at the intraenterocyte level.
Suitable candidates for administration in Piperine-PNL are listed
in Table 14.
TABLE-US-00015 TABLE 14 Examples of P-gp, CYP3A4 and
UDP-glucuronosyltransferase (UGT) enzymes substrates at the
gut-wall and the liver, which are suitable candidates for
administration in Piperine-PNL. Amlodipine Calcium channel blockers
Diltiazem Felodipine Nicardipine Nifedipine Nimodipine Nisoldipine
Verapamil Phenytoin Antiepileptics Cyclosporine Immunosuppressants
Sirolimus Tacrolimus Atorvastatin Statins Lovastatin Simvastatin
Fexofenadine Antihustamins Buspirone CNS drugs
Results of CBD-Pro-Nano Lipospheres Incorporating Curcumin,
Resveratrol and Piperine as Absorption Enhancers
[0257] The results in FIG. 16 and Table 15 show that administration
of CBD-piperine-PNL resulted in significantly higher oral relative
bioavailability in comparison to all the tested formulations, when
administered to rats. Oral administration of CBD-piperine-PNL
resulted in significantly higher AUC and Cmax values by 5 fold and
15 fold, respectively, as compared to control.
TABLE-US-00016 TABLE 15 PK parameters (mean .+-. S.E.M.) derived
from PO administration of CBD and CBD-Piperine 2%-PNL to rats; (n =
6 for each group). *Significant difference (p < 0.05) from CBD
corresponding value is found. .dagger.Significant difference (p
< 0.05) from (CBD-PNL) corresponding value is found. C.sub.max
(ng/mL) AUC (h * ng/mL) CBD 39 .+-. 8 90 .+-. 21 CCBD-Piperine 170
.+-. 13(*) 570 .+-. 23 (*.dagger.) 2%-PNL
[0258] It is noted that curcumin could not be effectively
incorporated into PNL system. The incorporation of curcumin
resulted in its precipitation following the introduction of the
pre-concentrate (containing piperine) into the water phase
in-vitro. The same effect most probably occurs in-vivo. Moreover,
as the absorption of CBD following CBD-curcumin 1% or 2%-PNL is
lower as compared to CBD-PNL it is reasonable to assume that the
incorporation of curcumin damages the proper formation of the CBD
nano-lipospheres resulting in poorer oral bioavailability of
CBD.
[0259] Though the incorporation of both resveratrol and piperine
results in homogeneous and visually clear pre-concentrate the oral
bioavailability of CBD is enhanced only when the delivery system
contains piperine.
[0260] Curcumin, resveratrol and piperine were reported, in the
literature, to successfully enhance the bioavailability of several
lipophilic compounds. The proposed mechanisms behind this
phenomenon are: CYP P450 inhybition, p-glycoprotein (p-gp) efflux
reduction and inhibition of phase 2 metabolism. Due to its poor
aqueous solubility, curcumin can be incorporated into the lipid
Self-nanoemulsifying drug delivery systems (SNEDDS) core. This
incorporation increases curcumin concentration that reaches the
intestine and the liver, and competitively inhibit CBD metabolism
in those metabolic sites.
[0261] Thus, incorporation of piperine into SNEDDS increases the
plasma concentrations of THC and CBD.
A Selection of an Absorption Enhancer for the Development of
Various Pro-Nano-Lipospheres Containing an Absorption Enhancer and
Several Different Lipophilic Drugs
[0262] The development of each of the formulations, in terms of a
selection of the different components, was conducted by the
following method. A combination of certain components was used as a
reference starting point (as per Table 16). The choice of these
certain triglyceride, organic amphiphilic co-solvent and the
combination of surfactants in the detailed portions in Table 16 was
based on the inventors' previous experience with various lipophilic
drugs. Thus, an absorption enhancer was added to this specified
prototype formulation to form a pre-concentrate. In case this
prototype formulation was failed to efficiently dissolve the
absorption enhancer or in case a precipitation of an absorption
enhancer was observed following the introduction of the
pre-concentrate to a water phase, a replacement of triglyceride
or/and organic co-solvent was performed.
TABLE-US-00017 TABLE 16 Curcumin-ProNanoLipospheres development
Pre- Pre- Pre- Pre- Pre- concen- concen- concen- concen- concen- %
(w/w) trate 1 trate 2 trate 3 trate 4 trate 5 curcumin 1 2 tween 20
12.5 span 80 12.5 lecithin 9 HCO 40 12.5 ethyl lactate 37 36 N-
methyl- pyrolidone trilaurin 12.5 tripalmitin 12.5 trimyristin 12.5
tricaprine 12.5
[0263] Incorporation of curcumin into all five formulations formed
a pre-concentrate in which curcumin was fully dissolved. However,
upon dilution with water phase, curcumin at the concentration of 1%
and 2% precipitated immediately from pre-concentrates 2, 3, 4 and
5. The same effect most probably occur in-vivo. Only
pre-concentrate 1 following dilution with water phase formed a
nanodispersion system which was stable, i.e. no precipitation of
curcumin at the concentration of 1% and 2% was observed, for 10 min
at 37.degree. C., giving sufficient time window to perform
pre-clinical studies. Thus CBD 3% was added to these formulations
to form two pre-concentrates; CBD-curcumin 1%-PNL and CBD-curcumin
2%-PNL. Following introduction of these two pre-concentrates to
water phase nano-dispersions were formed. No precipitation both of
the active ingredient (CBD) and of the absorption enhancer
(curcumin) was observed for 10 min at 37.degree. C. following
dilution. Thus CBD-curcumin 1% and CBD-curcumin 2%-PNL were tested
in pre-clinical trials. The oral administration of CBD-curcumin 1%
and 2%-PNL resulted in significantly lower AUC and Cmax values as
compared to the oral administration of CBD-PNL to rats. Moreover,
the oral administration of CBD-curcumin 1% and 2%-PNL didn't
enhance the oral bioavailability of CBD as compared to the
administration of CBD alone. Thus, it is reasonable to assume that
the incorporation of curcumin damages the proper formation of the
CBD nano-lipospheres upon introduction to water phase, i.e. the
fluids of the gastrointestinal tract, resulting in poorer oral
bioavailability of CBD.
TABLE-US-00018 TABLE 17 Resveratrol and piperine -
ProNanoLiposphere development Pre- Pre- % (w/w) concentrate 1
concentrate 2 resveratrol 2 piperine 2 tween 20 12.5 span 80 12.5
lecitin 9 HCO 40 12.5 ethyl lactate 36 tricaprine 12.5
[0264] The incorporation of both resveratrol and piperine formed
homogeneous and visually clear pre-concentrate. No precipitation of
both resveratrol and piperine were observed upon dilution of these
pre-concentrates with water. Thus CBD 3% was added to these
formulations to form two pre-concentrates; CBD-resveratrol-PNL and
CBD-piperine-PNL. Following introduction of these two
pre-concentrates to water phase a stable and visually clear
nano-dispersions were formed. No precipitation both of the active
ingredient (CBD) and of the absorption enhancers (resveratrol and
piperine) was observed for up to two month following dilution.
Thus, these two formulations were tested in pre-clinical
trials.
[0265] All the selected and tested materials curcumin, resveratrol
and piperine were reported to enhance the oral bioavailability of
various lipophilic compounds in-vivo, thus are referred to as
"absorption enhancers". Moreover, both CBD-resveratrol-PNL and
CBD-piperine-PNL showed favorable stability characteristics as
compared to CBD-curcumin 1% and 2%-PNL. However, results of
pre-clinical studies indicated that only CBD-piperine-PNL oral
administration resulted in significant enhance in the
bioavailability of CBD as compared to the administration of CBD-PNL
and the administration of CBD alone.
[0266] Testing the Compatibility of Various BCS Class II and Class
IV Drugs with the Pre-Concentrate:
[0267] In order to determine the compatibility of the developed PNL
delivery system with various lipophilic drugs, we have tested the
ability of the piperine-PNL to dissolve various BCS class II and IV
drugs. Incompatibility was determined if the pre-concentrate were
unable to fully dissolve the tested drug or if the tested
drug-piperine-PNL were not able to self-emulsify upon gentle
agitation in aqueous environment or resulted in unstable dispersion
system.
TABLE-US-00019 TABLE 18 Testing the compatibility of various BCS
class II and class IV drugs with the pre-concentrate. Tetra- hydro-
Ampho- canna- % tacro- amio- tericin simvas- cyclo- binol (w/w)
limus darone B tatin sporine (THC) piperine 2 tween 20 13 span 80
13 lecitin 9 HCO 40 13 ethyl 37 lactate trilaurin 13 tricaprine
13
[0268] Amphotericin B was found to be incompatible with the
pre-concentrate. The rest of the drugs tested were found to be
compatible with the pre-concentrate and upon dilution with water
formed clear and transparent nano-dispersion systems with desirable
range (less than 200 nm) of the size of the particles formed.
CBD//CBD-THC//tacrolimus and cyclosporine piperine-PNL formed
nano-dispersion systems of optimal particle size <50 nm. The
exception was pre-concentrate incorporating Amiodarone which when
dispersed formed particles of 276 nm (Table 18).
[0269] A Detailed Description of the Compatibility Characteristics
of the Tested Compounds with the Piperine-PNL
[0270] Amphotericin-piperine-PNL: The drug did not dissolve in the
pre-concentrate.
[0271] Cyclosporine-piperine-PNL: the drug was fully dissolved in
the pre-concentrate. Upon dissolution of the pre-concentrate with
water, a clear and transparent dispersion was formed.
[0272] THC-CBD-piperine-PNL: the drug was fully dissolved in the
pre-concentrate. Upon dissolution of the pre-concentrate with
water, a clear and transparent dispersion was formed.
[0273] Tacrolimus-piperine-PNL: the drug was fully dissolved in the
pre-concentrate. Upon dissolution of the pre-concentrate with
water, a clear and transparent dispersion was formed.
[0274] Simvastatin-piperine-PNL: the drug was fully dissolved in
the pre-concentrate. Upon dissolution of the pre-concentrate with
water, clear opal white dispersion was formed. No precipitation of
the drug was observed up to 2 h post dissolution.
[0275] Amiodarone-piperine-PNL: the drug was fully dissolved in the
pre-concentrate. Upon dissolution of the pre-concentrate with
water, milky white dispersion was formed, implying an
insufficiently large mean droplet size. No precipitation of the
drug was observed up to 2 h post dissolution.
TABLE-US-00020 TABLE 19 Particle size and polydispersity index
(PdI) of the different PNLs following 1:10 dilution with water.
Particle size and 70 potential were determined using Zetasizer Nano
ZS ZEN 3600 (Malvern Instruments Ltd, Malvern, UK). ***Polysorbate
20 (Tween .RTM. 20), Sorbitan monooleate 80 (Span .RTM. 80),
Polyoxyethylene hydrogenated castor oil 40 (HCO-40). Size nm
formulation (diameter) PdI CBD-piperine-PNL 30 0.23
Cyclosporine-piperine-PNL 26 0.2 Simvastatin-piperine-PNL 76 0.53
Tacrolimus-piperine-PNL 38 0.34 THC-CBD-piperine-PNL 40 0.25
Amiodarone-piperine-PNL 276 0.41 CBD-resveratrol-PNL 65 0.5
* * * * *